"Green Prescription: The Role of Leadership in Fostering Environmental Sustainability in Pharmaceuticals"

"A QUALITATIVE INVESTIGATION INTO LEADERSHIP'S ROLE IN INTEGRATING ENVIRONMENTAL SUSTAINABILITY WITHIN THE PHARMACEUTICAL INDUSTRY: CHALLENGES, STRATEGIES, AND FUTURE DIRECTIONS"

Research Thesis

Course Title: M.Sc. International Business

Presented By: Soumya Bhupesh Mishra

Supervised By: Dr. Eileen Tan

Student Number: 22163158

Submitted to the National College of Ireland: May 6, 2024

INDEX

Submission of Thesis and Dissertation

National College of Ireland

Research Students Declaration Form

(Thesis/Author Declaration Form)

Name: Soumya Bhupesh Mishra

Student Number: 22163158

Degree for which thesis is submitted: MSc. International Business

Material submitted for award

(a) I declare that the work has been composed by myself.

(b) I declare that all verbatim extracts contained in the thesis have been distinguished by quotation marks and the sources of information specifically acknowledged.

(c) My thesis will be included in electronic format in the College Institutional Repository NORMA (thesis reports and projects).

(d) ***Either*** *I declare that no material contained in the thesis has been used in any other submission for an academic award.

Or *I declare that the following material contained in the thesis formed part of a submission for the award of

_____

(State the award and the awarding body and list the material below)

Signature of research student: 

Date: 06/05/2024

All thesis submissions must be accompanied by a thesis submission form. The current guidelines for submission are available through the library at the following URL: http://libguides.ncirl.ie/thesisguide. The guidelines specific to the School of Business guidelines are listed here: https://libguides.ncirl.ie/business.

Submission of Thesis to Norma Smurfit Library, National College of Ireland

Student name: Soumya Bhupesh Mishra Student number: 22163158

School: Business Course: MSc International Business

Degree to be awarded:

MSc. International Business

Title of Thesis:

An electronic copy of your thesis will be lodged in the Norma Smurfit Library and will be available for consultation. This electronic copy will be accessible in NORMA norma.ncirl.ie the National College of Ireland's Institutional Repository. In accordance with normal academic library practice all theses lodged in the National College of Ireland Institutional Repository (NORMA) are made available on open access.

I agree to an electronic copy of my thesis being available for consultation within the library. I also agree to an electronic copy of my thesis being made publicly available on the National College of Ireland's Institutional Repository NORMA.

Signature of Candidate:



For completion by the School:

The aforementioned thesis was received by _____

Date: _____

This signed form must be appended to all copies of your thesis submitted to your school.

ACKNOWLEDGEMENT

I would like to extend my deepest gratitude to a number of individuals and groups who have supported me throughout the completion of this thesis.

Firstly, I am immensely thankful to my supervisor, Eileen Tan, for her invaluable guidance, patience, and expertise. Her insights and suggestions have been crucial in shaping this research, and her encouragement sustained me through challenges.

I also owe a great deal of thanks to all the interview participants whose perspectives and experiences were vital to my study. Your willingness to share your knowledge has significantly enriched this work.

My appreciation also goes to the lecturers and support staff at NCI, whose dedication to student success has not gone unnoticed. Your efforts have created a nurturing and intellectually stimulating environment that has greatly benefited my academic journey.

Lastly, I must express my profound gratitude to my partner, Saksham Doshi, for his unwavering support, patience, and love. Your constant encouragement and belief in me have been sources of strength and motivation.

Thank you all for your part in my academic journey.

APPENDIX

IMPORTANT TERMS AND DEFINITIONS

- Sustainability - In order to be sustainable, current demands must be met while preserving the capacity of future generations to satisfy their own needs from an ecological, social, and economic standpoint.
- Environmental sustainability - which emphasizes resource depletion, energy efficiency, and waste reduction, seeks to satisfy present human demands without endangering the environment's capability for future generations.
- Green chemistry - the design of chemical products and processes to reduce the usage and creation of hazardous substances, as well as the promotion of sustainable pharmaceutical practices that reduce the negative effects of medication production on the environment.
- Life Cycle Assessment (LCA) - Pharmaceutical firms utilize the Life Cycle Assessment (LCA) methodology to evaluate the environmental effect of their goods and processes throughout the course of their life cycle.
- Sustainable leadership - The practice of sustainable leadership entails leaders who recognize and tackle sustainability issues, guaranteeing the long-term sustainability of interdependent living systems while juggling the demands of the social, political, and environmental spheres.

LIST OF FIGURES

ABSTRACT

This dissertation investigates the critical role of leadership in promoting environmental sustainability within the pharmaceutical industry in Ireland, examining how leaders can influence the development, manufacturing, and distribution of eco-friendly pharmaceutical products. Adopting a qualitative research methodology, the study involved semi-structured interviews with key industry leaders to gather deep insights into their strategies and the challenges they face in integrating sustainability into their operations.

The findings reveal that effective leadership is essential for fostering an organizational culture that prioritizes sustainability. Leaders who integrate environmental considerations into business strategies not only comply with regulatory demands but also drive innovation in sustainable practices. The study highlights various leadership styles and their effectiveness in overcoming barriers to sustainability, such as cost and regulatory compliance.

Significantly, the research underscores the necessity for pharmaceutical companies to align their operational and strategic initiatives with environmental sustainability to mitigate their ecological footprint while ensuring economic viability. This alignment is crucial in addressing the pressing global challenges of environmental degradation and climate change.

By exploring the interplay between leadership, sustainability, and corporate practices, this dissertation contributes to a better understanding of the pharmaceutical sector's potential to lead in environmental stewardship, offering valuable insights for policymakers, industry leaders, and sustainability advocates.

CHAPTER 1: INTRODUCTION

1.1 RESEARCH BACKGROUND

The pharmaceutical business is a modern sector that concentrates on studying and evaluating, creating and inventing, and producing, and advertising medications and medical treatments. Finding novel drugs or improving ones that already exist that can prevent, diagnose, and treat illnesses while also enhancing patients' quality of life is the main objective of the industry (Sonneveld *et. al*, 2013). This sector of the economy deals with a broad range of goods, including as biologics, over-the-counter medicines, prescription pharmaceuticals, and vaccinations. To guarantee the safety and effectiveness of pharmaceutical goods, it is typified by stringent regulatory requirements, clinical studies, and rigorous research and development (R and D) procedures. By developing cutting-edge therapies for a wide range of illnesses, the pharmaceutical industry contributes significantly to the improvement and extension of human life stands at a crucial crossroads, where the imperatives of environmental sustainability to fulfil present requirements without jeopardizing environmental sustainability, or the capacity of future generations to satisfy their own needs, is the wise use and management of natural resources (Li, 2023). It comprises practices and policies intended to preserve ecological balance, minimize impact on the environment, and safeguard natural resources. Conserving energy and water, cutting down on waste and pollution, preserving ecosystems and biodiversity, and advancing sustainable agriculture and renewable energy sources are all important components of environmental sustainability. The goal is to establish a sustainable economy that functions within the constraints of earth's natural processes, guaranteeing the health and plenty of the planet's resources for coming generations (Milanesi et. al, 2020) corporate leadership in pharmaceutical companies involves guiding and managing the organization towards achieving its business goals, particularly in developing, manufacturing, and marketing medicinal products (Jung, Wu and Chow, 2008). This leadership encompasses setting strategic directions, fostering innovation in drug development, ensuring regulatory compliance, and maintaining, pharmaceutical business leaders confront difficulties (Spinello, 1992).

Effective corporate leadership in this sector requires a deep understanding of the scientific and healthcare landscapes, strong business acumen, and a commitment to improving patient health outcomes while achieving financial success. (Nguyen, Mai and Huynh, 2019). This dissertation embarks on an exploratory journey to scrutinize the pivotal roles that leadership plays in fostering, promoting, and implementing environmentally sustainable practices within the pharmaceutical sector. Products that minimize their environmental effect throughout their lifespan are considered sustainable. This covers procurement, production, packaging, and disposal (Milanesi, et. al, 2020)

Given the industry's significant impact on global health research and development, productivity declines due to rising costs, increased project failure rates, and organizational challenges (Jang et. al, 2017), but emerging trends could boost future productivity (Milanesi et. al, 2020) and its substantial environmental footprint, this investigation is not only timely but also critical. Integrating environmentally friendly practices across the supply chain, from procuring raw materials to production and distribution, requires a leadership commitment to sustainability (Kumar et. al, 2018) The development, manufacturing, and distribution of pharmaceuticals and other healthcare items are activities that have a substantial influence on the environment. Prioritizing sustainability is crucial if we want to lessen this effect while still offering vital healthcare solutions. This entails lowering expenses, quickening the pace of product creation, and improving quality (Kola and Landis, 2004). These companies must continuously spend in R&D to make sure their goods and services satisfy consumer wants if they want to be competitive on a global scale (Afsar et. al, 2018).

The pharmaceutical industry is uniquely positioned due to its dual responsibility: ensuring the health of the populace while simultaneously mitigating its environmental impacts (Hernando *et. al*, 2006). This dichotomy presents a complex challenge for industry leaders, who must navigate regulatory landscapes, market pressures, and ethical considerations to steer their organisations towards more sustainable practices (Berry and Rondinelli, 2000). The role of leadership therefore, becomes paramount in this context, as it can catalyse or hinder the use of ecologically friendly goods and methods (Evans et. al, 2015).

Green Supply Chain Initiatives showcases how leadership can manage environmental risks and promote sustainability (Green *et. al*, 2012). Strategic leadership is necessary to prioritize and effectively implement these initiatives,

highlighting the role of leaders in achieving focus on cleaner production and operational sustainability. The importance of environmental sustainability in management studies is highlighted by the pharmaceutical industry's emphasis on greener supply chains, cleaner production methods, and sustainable human resource management (Ding, 2018). It will take leadership in this field to handle issues like waste management and the financial effects of new medications in the future (Milanesi et. al, 2020).

The manufacturing sector's growth is causing environmental issues like resource depletion and rising global temperatures. Companies must adapt and consider social obligations to adapt. The pharmaceutical industry faces global challenges, and sustainability is becoming a global imperative, focusing on sustainable medication research, production, and waste management. (Jia et. al, 2018).

Inspirational motivation is a leader's application of vision and high expectations to inspire a strong work ethic and commitment to an organisation's objectives. Studies on green innovation and corporate environmental ethics are growing, with upper-echelon theory suggesting senior managers' perspectives influence strategic decision-making and ethical leadership influences environmental innovation. (Liao and Zhang, 2020)

Leadership Theories and Models in Promoting Sustainability

- **Sustainable Leadership**: Sustainable leadership incorporates social, ethical, and environmental factors in addition to the conventional emphasis on financial achievement. Adopting this paradigm, leaders put long-term sustainability ahead of short-term advantages, which is essential for tackling the environmental implications of the pharmaceutical sector (Ferdig, 2007).
- **Strategic Leadership for Corporate Sustainability**: Strategic leadership involves integrating sustainability into the core business strategy and aligning environmental goals with business objectives. This approach is essential for pharmaceutical companies aiming to balance economic success with environmental stewardship (Strand, 2014).

The goal of this dissertation is to examine the various aspects of leadership in the pharmaceutical sector in Ireland, with a particular emphasis on how leaders may promote the creation, manufacturing, and distribution of environmentally friendly goods. (Metcalf and Benn, 2012). It will examine various leadership theories and

models to understand their applicability and effectiveness in fostering sustainability within the pharmaceutical context. In addition, the study will include case studies and empirical evidence to shed light on the approaches, obstacles, and achievements faced by executives in their pursuit of sustainability that are in line with corporate objectives and environmental stewardship.

This dissertation provides a thorough analysis of how leadership may operate as a catalyst for environmental sustainability in the pharmaceutical business, essentially bridging the gap between theoretical leadership structures and real sustainability outcomes. It hopes to provide insight into the ways in which the pharmaceutical industry might support a future that is more environmentally friendly and health conscious.

1.2 PROBLEM STATEMENT

The pharmaceutical business is leading the way in tackling some of the most important health issues of our day because it puts short-term profits ahead of long-term environmental sustainability (Berry and Rondinelli, 2000), yet it also faces intense scrutiny due to its environmental impact. The production, distribution, and disposal of pharmaceutical products contribute significantly to environmental degradation, including but not limited to, water pollution, greenhouse gas emissions, and non-biodegradable waste (Weaver et. al, 2022). Despite increasing global awareness and demand for environmentally sustainable practices, the pharmaceutical industry encounters substantial barriers in integrating sustainability into its core operations. One of the most critical yet underexplored barriers is the part that leadership plays in directing the sector toward more environmentally friendly procedures and goods (Tuan, 2019). Proficient leaders understand the significance of including several stakeholders, such as staff members, clients, and the broader community, in the organisation's environmental objectives (Jang et. al, 2017).

Leadership within the pharmaceutical sector has a profound impact on organisational culture, strategic direction, and operational practices (Weaver et. al., 2022). However, there is a palpable gap in understanding how leadership approaches and styles influence the adoption and implementation of environmentally sustainable innovations in pharmaceutical products. Milanesi et. al (2020) This gap is not merely academic but has real-world implications for the pace and extent to which the

pharmaceutical industry can mitigate its environmental footprint while continuing to deliver life-saving drugs and treatments.

The pharmaceutical sector faces many obstacles in its pursuit of sustainability. Getting the right medications at the right price while maintaining environmentally responsible methods may be a challenging endeavour. Complicated supply chains and profitability worries might be further obstacles. Sustainability concerns have led to stricter rules for the pharmaceutical and life sciences industries, including price controls, carbon taxes, and prohibitions on pesticides and antibiotics in agriculture (Ding, 2018). Eco-friendly supply chains and industrial methods can protect the environment. The pharmaceutical sector faces environmental issues due to its extensive global supply chains, high energy consumption, pollution, and packaging waste (Aus der Beek et. al, 2020) long-term success requires corporate digital responsibility, compliance, openness, and integrity. In 2015, the pharmaceutical sector produced 52 megatons of CO2e, surpassing the automobile industry's 46.4 megatons. *(Wilkinson et. al, 2022)*.

The pharmaceutical industry faces challenges in implementing sustainable practices due to strict regulations, complex supply chains, and ethical and social accountability issues. Companies must consider environmental implications and develop robust metrics to ensure sustainability. A comprehensive strategy with strong leadership, clear rules, and collaboration with regulatory agencies is needed. Current literature focuses on technical and legal aspects, neglecting organizational and human factors. Comprehensive studies on leadership, organizational culture, and environmental sustainability are needed to accelerate the shift to ecologically sustainable activities. (Ding, 2018).

1.3 SCOPE OF THE STUDY

The scope of this study encompasses several critical areas within the pharmaceutical industry, aimed at understanding and enhancing the role of leadership in promoting environmental sustainability alongside public health:

- **Industry leadership:** Analysis of leadership strategies and roles that have successfully integrated sustainable practices within pharmaceutical companies, and how these can be modelled industry wide.
- **Sustainability initiatives:** Examination of current sustainable practices, including waste reduction, energy efficiency, and sustainable sourcing, and their impact on reducing the environmental footprint of pharmaceutical companies.

- **Financial analysis:** A detailed exploration of the economic implications of integrating sustainability into pharmaceutical practices, including cost-benefit analyses, investment strategies, and the financial health of adopting sustainable innovations.
- **Innovation and technology:** Investigation of cutting-edge sustainable technologies and practices in drug formulation, packaging, and distribution, and their potential for industry-wide adoption.
- **Global standards and collaboration:** Discussion on the importance of establishing global sustainability standards and the role of international collaboration among pharmaceutical companies, regulatory bodies, and other stakeholders in fostering a more sustainable industry.

This comprehensive study aims to catalyse significant advancements in sustainable drug manufacturing and distribution, ultimately contributing to a healthier planet and society.

1.4 RESEARCH OBJECTIVES

- This dissertation aims to examines the pharmaceutical industry's leadership positions, focusing on environmentally friendly products, regulatory influences, sustainable practices, supply chain sustainability, resistance to change, measurement and reporting, and intellectual property collaboration.
- It seeks aims to address financial strains, research obstacles, regulatory uncertainty, internal resistance, environmental impact measurement, global reach, ethical and social accountability, intellectual property concerns, and ambitious investment returns.
- The study highlights the challenges faced by companies in understanding the environmental implications of pharmaceutical products, navigating regulatory uncertainties, measuring environmental impact, and coordinating policies across countries. The findings offer valuable insights into the leadership roles and policies driving the development and execution of environmentally sustainable products.

1.5 RESEARCH QUESTIONS

1. What are the key leadership roles in pharmaceutical companies and strategies that influence the development and implementation of environmentally sustainable products?

2. What are the main challenges faced by pharmaceutical companies in integrating environmental sustainability into their operations, supply chain, and product development processes?
3. What methods and standards are used by pharmaceutical companies for measuring and reporting the environmental impact of their products, and how does leadership ensure transparency and accountability in this process?

Sub-Questions:

1. What are the internal and external factors that may hinder or facilitate the adoption of sustainable practices within pharmaceutical companies?
2. What are the lessons learned from existing examples of pharmaceutical companies that have successfully implemented sustainable practices?
3. What are the future trends and challenges that the pharmaceutical industry will face in balancing environmental sustainability with financial success?

1.6 SIGNIFICANCE OF THE STUDY

This research holds critical significance in the pharmaceutical industry, a sector with profound implications for environmental sustainability, public health, and well-being. By focusing on leadership roles in reducing carbon emissions and other pollutants, the study addresses a pivotal gap in understanding how industry leadership can foster a balance between sustainability and public health interests. The significance of the study is multifaceted:

- **Environmental impact reduction:** It underscores the urgent need to minimize the pharmaceutical sector's environmental footprint, offering a roadmap for leadership to implement sustainable practices effectively.
- **Public health enhancement:** The study bridges the gap between environmental sustainability and public health, showcasing how pharmaceuticals, while essential for health, can also be produced and disposed of in ways that protect the environment.
- **Economic viability:** By examining the financial implications of sustainability initiatives, the study provides invaluable insights into how companies can maintain economic viability while pursuing sustainable practices, a crucial balance for the industry's long-term success.
- **Innovation and competitive advantage:** Highlighting innovation in sustainable practices, the research argues that such advancements can serve as a

competitive edge, encouraging further industry-wide adoption and stimulating research in sustainable technologies.

- **Global collaboration and ethical implications:** Advocating for global collaboration and standardization of sustainability practices, the research emphasizes the ethical obligations of the pharmaceutical industry to society and the environment, promoting social responsibility and trust.

1.7 RESEARCH METHODOLOGY

The research methodology employed in this study is qualitative. The study aims to gain insight into the leadership positions pertaining to environmentally friendly goods in the pharmaceutical business. Networking and semi-structured interviews with important industry players, including CEOs, sustainability officers, and other senior management, are one of the main techniques used to collect data. To complement the results of the interviews, document analysis of public disclosures and business sustainability reports will be done. Additionally, an extensive literature review focused on leadership roles and sustainability in the pharmaceutical industry will be conducted. The study will be measured against already conducted case studies and data to get the best results.

The data analysis will gather interviews, document analysis, and literature review to provide insights into leadership positions, industry players, and stakeholders.

CHAPTER 2 – LITERATURE REVIEW

2.1 INTRODUCTION

Creating a comprehensive literature review on the study of leadership roles for environmentally sustainable products in the pharmaceutical industry requires a nuanced approach, given the specificity of the topic.

This review explores leadership roles in promoting environmentally sustainable products in the pharmaceutical industry, focusing on environmental sustainability, consumer behavior, and implications. It examines barriers and enablers to sustainable practices, theoretical framework, future directions, and leadership strategies, drawing on current literature.

Environmental Sustainability Practices in the Pharmaceutical Industry

The study by Archer et al. (2017) offers a comprehensive examination of the effects of pharmaceuticals, personal care items, endocrine-disrupting substances, metabolites, and illegal drugs on the environment. It particularly highlights how these contaminants persist and spread within wastewater treatment facilities and natural water bodies. Additionally, Mo et al. (2017) investigated the relationship between ethical leadership and outcomes for employees, including burnout, deviant behaviour at work, and performance levels. The research stressed the critical role of ethical leadership in fostering a healthy workplace atmosphere, crucial for encouraging sustainable practices in pharmaceutical organizations. Bagheri et al. (2017) examined the process of photocatalysis in breaking down pharmaceutical pollutants in the environment. Hayler et al. (2018) study's results enhance knowledge on sustainable techniques for reducing the environmental effects of pharmaceutical remnants offered insights from the pharmaceutical sector on sustainable metal catalysis, emphasizing the opportunity to adopt eco-friendly catalytic methods in drug production that could help minimize the environmental impact.

This thesis explores the role of leadership in guiding companies towards environmentally sustainable products, focusing on the pharmaceutical industry's approach to meet sustainability expectations and contribute to global sustainability efforts, highlighting gaps in current knowledge.

2.2 CONSUMER BEHAVIOR AND PREFERENCES

Consumer preferences have significantly shifted towards environmentally sustainable products, including pharmaceuticals in recent years. Royne et al. (2011) Consumers are increasingly willing to spend on eco-friendly, quality products, influencing companies' product development and marketing strategies, highlighting the importance of corporate social responsibility in influencing consumer decisions. Jones et al. (2023) Studies highlight the need for pharmaceutical industry leaders to adapt business strategies to meet consumer expectations, focusing on eco-sustainable products and implementing Green Supply Chain (GSC) practices. Kumar et al. (2018) The text emphasises the significance of identifying and mitigating potential risks in implementing GSC strategies for sustainability, emphasizing the need for leadership commitment throughout the supply chain.

2.3 LEADERSHIP AND ENVIRONMENTAL SUSTAINABILITY

Leadership involves guiding a group or organisation towards a common goal, using various approaches like autocratic, democratic, transformational, or transactional styles, depending on the situation and individuals involved. (Khan et. al, 2014)

The importance of leadership cannot be overstated, as it plays a critical role in every sector of society, including business, politics, communities, and non-profit organizations. Effective leadership is crucial for several reasons:

- **Vision and direction:** Leaders provide a clear vision and direction for the future, helping individuals and organizations to understand and align with their goals and objectives (Sundgren et. al, 2002).
- **Motivation and inspiration:** Through their actions and words, leaders can inspire and motivate those around them to put forth their best efforts towards achieving common objectives (Douglas et. al, 2010).
- **Change management:** Leaders are often at the forefront of initiating and managing change within organizations, ensuring that transitions occur smoothly while minimising resistance and maintaining morale (Cockburn et. al, 2004).
- **Decision-making:** Good leadership involves making informed decisions, often under pressure. Leaders must assess situations, consider the implications of their

choices, and decide the best course of action for the collective benefit (Vuorenkoski et. al, 2008).

- **Developing others:** Leaders play a crucial role in the development of team members, offering guidance, training, and opportunities for growth. This not only improves individual performance but also benefits the organisation (Cockburn et. al, 2004).
- **Crisis management:** In times of crisis, effective leadership is vital to navigate challenges, make critical decisions, and communicate effectively with stakeholders to minimize impact and guide the organization towards recovery (Priporas et. al, 2008).
- **Building culture:** Leaders significantly influence the culture of their organizations. Through their behaviors, values, and norms, they shape the working environment, impacting employee satisfaction, performance, and retention (O'Connell et. al, 2007).

Leadership involves influencing others towards a common goal, requiring skills like emotional intelligence, strategic thinking, empathy, and communication, leading to increased productivity, employee engagement, innovation, and sustained success (Hui Li et. al, 2019).

Leadership styles in the pharmaceutical industry vary significantly, impacting organizational culture, innovation, and performance. Transformational leadership is particularly relevant due to the industry's need for innovation, strict regulatory compliance, and research and development. Transformational leaders inspire teams to exceed expectations, foster creativity, and develop new drugs and therapies (Hui Li et al; 2019).

Democratic Leadership: Given the collaborative nature of pharmaceutical work, involving research, development, trials, and marketing, democratic leadership can be quite effective. This style involves seeking input from team members and stakeholders, making decisions based on collective input. It supports a collaborative environment, encouraging the sharing of ideas and feedback, which can lead to better decision-making and innovative solutions (Foels et. al, 2000).

Servant Leadership: Servant leadership in the pharmaceutical industry fosters high employee engagement and loyalty, as it prioritizes the well-being of team members and the communities they belong to, thereby directly impacting patient and public well-being (Allen et. al, 2016).

Autocratic Leadership: Autocratic leadership, a unilateral decision-making style, is prevalent in industries like manufacturing and quality control, where strict compliance and accuracy are non-negotiable (Ahmed et. al, 2016).

Situational Leadership: Leaders in the pharmaceutical industry adopt situational leadership, adapting their style based on task, team needs, and challenges, crucial in a rapidly changing industry (Butler et. al, 2013)

Ethical Leadership: Ethical leadership in the pharmaceutical industry is crucial for patient safety, confidentiality, and fair clinical trials, ensuring transparency, integrity, and accountability for commercial success and societal benefit.

Effective pharmaceutical industry leaders adapt their leadership style to meet organizational needs, teams, and societal context, driving innovation, compliance, commercial success, ethical standards, and positive public health outcomes (Mulki et. al, 2009).

Leadership plays a critical role in integrating environmental sustainability into corporate strategy and operations. Jiang et al. (2017) Transformational leadership is crucial for promoting sustainability in an organization, as it inspires and motivates employees, directing the entire organization towards sustainable practices. Brown et al. (2023) Strategic leadership is crucial in navigating regulatory and competitive landscapes, ensuring organizations comply with environmental regulations and leverage sustainability as a competitive advantage. Rijal (2010) A study on leadership styles and organizational culture in learning organizations found supportive environments promote learning and innovation in pharmaceutical firms, but the effectiveness of these styles remains unclear. (Mulki et. al, 2009).

Nguyen et al. (2019) the study explores the impact of transformational leadership on work performance in Vietnam's pharmaceutical industry, suggesting potential relevance for the Irish pharmaceutical sector, highlighting its significant influence on intrinsic motivation.

Future Demets et al (2011) particularly in clinical trials Innovation and Leadership in fostering innovation in clinical trials, a notion especially pertinent to the pharmaceutical sector where research and development are key to success. Nevertheless, further investigation is necessary to grasp how leadership that fosters

pharmaceutical innovation can be best leveraged in the context of Ireland's pharmaceutical industry.

Leadership is essential in promoting environmental sustainability in the pharmaceutical sector (Portugal and Yukl, 1994). Berry et. al, (2000) International pharmaceutical companies are proactively addressing environmental management, focusing on sustainability. Leadership is crucial for effective environmental governance and sustainable development. Sustaining profitability for years provides a sustainable competitive advantage.

The pharmaceutical business in Ireland has thrived due to national policies, low industrialisation, industry-focused economic support packages, and geographical position, fostering competitiveness in the industry (Whelan 2013). However, because of greater competition brought about by the growth of a nearly uniform global market, Ireland can no longer only rely on supply-side variables that previously gave it competitiveness through what Porter (1998) dubbed "cost focus." Jang et al. (2017) highlight the crucial role of senior management's values and leadership in promoting environmental sustainability, emphasizing the strong influence of stakeholder involvement. Leadership theories focus on small-group phenomena, using styles like emotional intelligence, integrative approaches, social interaction approaches, and behavioral Approaches for direction, empowerment, and adaptability (Hogg et. al, (2001).

The pharmaceutical sector, responsible for 4.4% of global emissions, is significantly exacerbating climate change, with carbon dioxide emissions expected to quadruple by 2050 unless action is taken (Beek et al. 2016).

The study by Olivia et al (2021) the Irish pharmaceutical sector is undergoing a transformation towards Continuous Improvement (CI) strategies, including Lean Six Sigma, to improve business process performance. Lean Six Sigma, a combination of Lean manufacturing principles and Six Sigma's focus on quality control and precision, aims to streamline operations, minimise waste, and enhance product or service quality. The study reveals that a significant portion of participants (45%) perceive the heavily regulated environment as an obstacle to CI practices, but 97% of organizations use CI methods to boost productivity and quality. The regulatory landscape presents

challenges, such as apprehension about validation efforts and a culture that prioritizes compliance over quality improvement. However, the study highlights the deep integration of CI techniques within the industry's systems for corrective and preventative measures, managing deviations, and conducting internal audits.

The study explores the challenges and current state of Integrated Development (ID) initiatives in the pharmaceutical industry, providing insights for global pharmaceutical production. It emphasizes the need for leaders with exceptional capabilities to handle complexities and lead adaptive organizational transformations, emphasizing the importance of distinctive leadership frameworks.

The article Milanesi et al (2020) the pharmaceutical industry is focusing on sustainability due to consumer demands and policy changes. Key areas for sustainable practices include new delivery systems, products with reduced environmental impact, waste recycling, water reduction, greener production, and recyclable packaging. The focus is on achieving a balance between environmental, economic, and social sustainability.

2.4 THE PHARMACEUTICAL INDUSTRY

The pharmaceutical industry faces significant environmental challenges, including hazardous chemicals, water consumption, and waste generation. Leaders must implement innovative approaches to minimize environmental footprints while ensuring product efficacy and safety. Strategies like green chemistry, sustainable supply chain management, and lifecycle assessment can enhance environmental sustainability in pharmaceutical production. High energy use, supply network disruptions, and environmental contamination are significant environmental challenges. To ensure sustainability, the industry should improve manufacturing processes and streamline supply chains. (Wang et al, 2023).

Additionally, focusing on providing affordable medications and treatments to underfunded and underfunded healthcare systems in developing nations can contribute to social sustainability by providing affordable healthcare solutions Godman et al. (2015). Understanding sustainability's history and viewpoints is crucial due to its growing interest in the twenty-first century, new global economies, and environmental

consciousness, as it addresses resource usage hazards and exploitation risks. Pharmaceutical sector leaders face evolving stakeholder relationships, patent issues, healthcare reforms, technological advancements, policy changes, and shifting consumer expectations, while globalisation complicates marketing, regulatory, and compliance efforts (Milanesi et. al, 2020). Sustainability, eco-friendly practices, and CSR are crucial factors in the pharmaceutical industry. Effective leadership fosters a positive culture and profitability. Ireland, the world's second-largest drug exporter, is a key player in the global market. The economic crisis has raised concerns about sustainability and employee well-being.

Cost-Effectiveness and Rational Rationing: O'Mahony et al (2015) The study explores the Irish cost-effectiveness threshold's impact on healthcare rationing and leadership decisions in the pharmaceutical sector, highlighting the intricate interplay between economics and healthcare policies.

Corruption and Access to Healthcare: Bouchard, et al. (2012) The study examines corruption in Uganda's healthcare sector, highlighting its impact on orthopedic care and medical devices, highlighting ethical leadership and integrity issues within healthcare systems.

Exploring the prevalence and impact of corruption on leadership practices within the Irish pharmaceutical industry could provide valuable insights for organisational governance and policy development. Milanesi et al. (2020) The pharmaceutical industry's sustainability is crucial, requiring cleaner production, green supply chains, and sustainable human resource management. This requires strategic leadership that integrates sustainability into core business strategies. Strand (2014) The text discusses the rise of top management positions with corporate sustainability responsibilities, their impact on organisational practices, and the significance of leadership in establishing sustainability-focused bureaucratic structures.

The research emphasises the importance of sustainability in pharmaceutical governance, focusing on product quality, transparent communication, and ethical norms. It emphasizes the role of the state in economic development, particularly in the Irish pharmaceutical sector, and the potential of active industrial policy (O'Sullivan, 2000).

This study examines Ireland's healthcare system's sustainability, focusing on historical, financial, demographic, and policy factors. It highlights rising costs, aging populations, and chronic disease burden. The paper discusses ongoing reforms, health economics, and the COVID-19 pandemic's implications. It concludes that ongoing reforms and health economic principles can contribute to long-term sustainability (Ding 2018)

Theoretical Framework

The literature highlights the importance of leadership in promoting environmental sustainability in the pharmaceutical sector, emphasising initiatives related to green supply chains, stakeholder engagement, and the need for evolving leadership skills. A PESTEL analysis will explore the political, economic, sociocultural, technological, environmental, and legal dimensions affecting sustainability efforts. (Milanesi et. al,2020)

Political: (International and Domestic Regulation) The pharmaceutical sector is significantly influenced by political forces and regulations concerning environmental protection and pharmaceutical manufacturing standards. Leaders are tasked with manoeuvring through these diverse regulations to ensure adherence and advance sustainability efforts. (Evans et. al, 2015).

Economic: Leaders must balance initial costs of adopting eco-friendly practices with long-term financial benefits and innovation potential. Increased consumer and investor demand for corporate responsibility and sustainable offerings can push the industry towards greener practices, providing a competitive edge. (Anand et. al, 2019)

Sociocultural: Increased public awareness and employee preferences in the pharmaceutical sector are driving companies to prioritise sustainability, attracting and retaining skilled personnel. (Katz et. al, 2022).

Technological: Technological advancements in pharmaceutical production and monitoring and analytics technology are enhancing efficiency, reducing waste, and conserving energy, prompting leaders to invest in sustainable technologies (Petrini et. al, 2009).

Environmental: The pharmaceutical industry faces challenges in reducing its environmental footprint due to resource scarcity and the need for sustainable sourcing practices, exacerbated by climate change (Ghadge et. al, 2019).

Legal: Regulatory compliance and intellectual property considerations are crucial for the innovation and dissemination of sustainable technologies and practices in the global and national environmental sectors (Grabowski et. al, 2002)

In conclusion, the PESTEL analysis highlights the complex external factors influencing the pharmaceutical industry's sustainability strategy, emphasising the need for effective leadership to balance these elements, drive innovation, and maintain regulatory compliance. (Milanesi et. al, 2020)

Studies on Ireland's pharmaceutical sector's sustainability highlight innovation, policy interventions, and the evolution of sustainable products and services, providing key insights.

1. Innovation as a sustainability driver: Innovation is crucial for sustainable industrial growth in Ireland, especially in resource development and utilization, and the extent of innovation within Irish firms significantly contributes to this progress (O'Sullivan, 2000).
2. Success and challenges of the pharmaceutical sector: Ireland's pharmaceutical sector, despite its global success, faces challenges such as competitive corporate tax environment, educated workforce, and favorable industrial development strategies (Egeraat, 2012).
3. Development of sustainable products: The Environmentally Superior Products (ESP) project promotes sustainable practices in industrial enterprises, fostering cleaner production methods and sector innovation. (Maxwell and Vorst, 2003)**.**
4. Sustainable Policy Measures for Cost Management: The study emphasizes the need for fiscally responsible pharmaceutical cost containment policies that balance fiscal responsibility with economic viability, addressing public expenditures while considering broader economic implications. (Kenneally and Walshe; 2012)**.**

In summary, Ireland's pharmaceutical industry is achieving sustainable development through innovation, strategic policy implementation, and sustainable practices,

aligning with industrial growth objectives, despite financial downturn and credit crunch (Heyes et al, 2010).

2.5 CORPORATE SOCIAL RESPONSIBILITY IN PHARMACEUTICALS

ISO defines CSR as a strategy addressing social, economic, and environmental challenges for community benefit. Pharmacists are increasingly involved in CSR initiatives, as manufacturers value their medical knowledge. Many businesses exceed legal criteria and adhere to international standards like OHSAS 18001 or ISO 14000. Employees may not perceive a clear connection between these operations and business outcomes, possibly reflecting attitudes toward quality, finance, and human resources. (Min, Maung et. al, 2017)

This literature review focuses on the key aspects which are leadership, sustainability, and development as the literature shows that there is an inconsistency between them, and the employees have a larger responsibility to work towards sustainability and leadership also plays an integral part in the pipeline of information to be transferred.

2.6 OBSTACLES IN CULTIVATING LEADERSHIP WITHIN THE PHARMACEUTICAL SECTOR

INTRODUCTION

This literature review highlights the challenges and considerations for effective leadership in the pharmaceutical industry, including technological advancements, regulatory issues, and fostering a sustainable corporate culture.

Primary obstacles and insights:

1. **Adjusting to technological and regulatory shifts:** Leadership training initiatives should consider the pharmaceutical sector's rapid technological growth and regulatory changes, guiding these changes, ensuring adherence to regulations, and driving innovation (Megheirkouni et. al, 2020).
2. **Differentiating leadership from leader development:** The distinction between individual leadership skills development and organizational social capital cultivation is crucial for addressing the pharmaceutical industry's challenges and fostering a culture of innovation and problem-solving. (Day, 2000).

3. **Responding to pandemics and health emergencies:** The COVID-19 pandemic underscores the need for adaptable leadership in the pharmaceutical industry, enabling swift decision-making, effective care management, and community communication. (Abuhammad, 2022).
4. **Enhancing individual and organizational capabilities:** Effective leaders can address issues like poor medication adherence, antimicrobial resistance, and negative drug reactions by integrating training programs, supportive supervision, mentorship, and peer learning. (Konduri et al., 2017).
5. **Overcoming challenges in new product development:** The pharmaceutical industry's dynamic business landscape necessitates leaders who can adapt to technological and market trends, requiring innovative research and development strategies (Marques et. al, 2019).
6. **Encouraging an innovative and ethical culture**: The culture should foster innovation and ethical decision-making, ensuring effective technical decision-making for project success and pipeline quality (Cook et al., 2014).

Literature Gaps: In contrast, Archer et. al, (2017) research emphasizes the technical and environmental aspects of harsh compounds, employing quantitative methods to assess their levels and potential risks to ecosystems and human health, research interviewing pharmaceutical company management about sustainable practices would differ significantly in several key areas:

- **Corporate practices vs. environmental aspects:** Unlike Archer et al. (2017)'s This dissertation explores sustainability strategies, policies, and challenges in pharmaceutical companies, focusing on environmental science and their commitment to sustainable waste management.
- **Qualitative insights vs. quantitative Analysis:** The study will adopt qualitative methods, including corporate interviews, to explore the pharmaceutical industry's sustainability practices and identify discrepancies between current practices and optimal environmental health outcomes.
- **Source reduction and management vs. environmental fate of compounds:** Archer et al.'s study explores harmful compounds' environmental fate, while a corporate practice study investigates manufacturing, product formulation, and waste management changes to mitigate environmental impact.

- **Corporate responsibility and innovation vs. risk to ecosystems:** The approach would enhance Archer et al.'s environmental risk assessment by examining pharmaceutical companies' environmental responsibility and innovative practices to reduce their ecological footprint (Archer et. al, 2017).
- **Consumer perceptions of sustainability terms**: Consumers differentiate between terms like “eco-friendly” and “sustainable,” impacting their preferences and behaviors. Understanding these perceptions can help in marketing pharmaceutical products effectively (Campbell et. al, 2015).
- **Environmental sustainability in consumer behavior**: An extensive analysis underlines the significance of environmental sustainability in influencing consumer choices, pointing out the critical role of a green image, awareness about environmental issues, and the perceived impact as key factors (Han, 2021).
- **Sustainability and marketing strategies**: Understanding how consumers perceive the effort and impact of sustainable activities can guide marketing strategies to positively influence consumer perceptions towards environmentally sustainable pharmaceuticals (McDonald et al, 2006).
- **SHIFT Framework for sustainable behaviors**: This framework suggests that marketing strategies leveraging social influence, habit formation, and feelings can shift consumer behaviors towards sustainability, relevant for promoting sustainable pharmaceutical products (White et al, 2019).
- **Understanding eco-friendly consumer behavior**: Insights into consumer behavior towards environmentally friendly products, including the importance of awareness and government regulations, can be applied to the pharmaceutical sector to foster environmentally sustainable consumption (Yahya, et al, 2016).

Pharmaceutical companies should consider consumer knowledge, perceptions, and terms used to describe environmental sustainability in their products. Leveraging social influence, habit formation, and government regulations can enhance consumer engagement with environmentally sustainable products. Future research should explore green practices in production, supply chain, and drug development, as well as leadership's influence on green initiatives (Wijoyo et. al, 2020).

2.8 CONCLUSION

Leadership development in the pharmaceutical sector is complex, necessitating adaptations to technological and regulatory transformations, clarifying the distinction between leader and leadership development, readiness for health crises, enhancing personal and collective capacity, overcoming new product development hurdles, and nurturing an innovative and ethical culture. Tackling these issues demands a strategic approach to leadership development that focuses on both individual skills and fostering social capital within organizations.

CHAPTER 3 – RESEARCH METHODOLOGY

3.1 INTRODUCTION

The research methodology involves qualitative interviews to explore leadership roles, challenges, and sustainable practices in the pharmaceutical industry, focusing on environmental sustainability.

3.2 INTRODUCTION TO RESEARCH METHODOLOGY

This research explores leadership roles, challenges, and environmental sustainability integration in the pharmaceutical industry using a qualitative approach. The methodology focuses on nuanced strategies, obstacles, and practices, avoiding quantitative methods that simplify complex aspects and relying on statistics. (Timo Savela et. al; 2017). The approach needs insight in the experience, emotions, expectations, and opinions of an individual qualitative research techniques such as ethnography, grounded theory, and phenomenology are instrumental in decoding the significance of experiences within a study group. They bring to light new insights into the nuanced realities of people's everyday lives by uncovering new terminologies of pharmaceutical field (Grossoehme et. al, 2014) This also provided room for a mixed design approach that includes both qualitative and quantitative research approaches; however, this was not adopted due to time constraints.

This section introduces qualitative research design, focusing on semi-structured interviews for understanding environmental sustainability in pharmaceutical leadership and operations. Focus groups were dropped to provide more profound understanding, while thematic semi-structured interviews provide insights into industry stakeholders' experiences, perceptions, and strategic orientations. (Wibeck et. al; 2007)

The methodology section outlines a qualitative approach, involving participants from biotechnology and pharmaceutical fields, ensuring a mix of roles and perspectives. The study uses an interview guide and analytical strategies to extract meaningful themes from data, providing valuable insights into leadership and sustainability practices in the pharmaceutical industry (Rhodes & Moore, 2001).

This research explores the relationship between leadership, sustainability, and innovation, using a methodological framework that emphasizes depth and understanding, aiming to inform theory and practice in the pharmaceutical sector.

3.3 RESEARCH DESIGN

Semi-structured interviews are defined using an interview guide or a set of pre-planned questions, yet they maintain the flexibility to explore new paths as the conversation unfolds and the exploration of new topics that emerge during the conversation. This approach enables researchers to cover specific areas of interest while also adapting to the flow of dialogue and pursuing in-depth information based on respondents' answers.

3.4 CHOOSING BETWEEN INTERVIEW TYPES

The choice between semi-structured, unstructured, and structured interviews depends on research goals, topic nature, and understanding level. Semi-structured interviews offer comprehensive data and flexibility for exploring predetermined themes, while unstructured are suitable for exploratory studies and structured for high comparability and statistical analysis. (Adeoye-Olatunde and Olenik, 2021).

The study uses a qualitative research approach, involving semi-structured interviews, to explore the experiences and strategies of industry leaders in the pharmaceutical industry. It aims to understand the challenges to sustainability, leadership roles, regulatory frameworks, and intellectual property collaborations, enabling a comprehensive understanding of their impact on environmental sustainability (Shashi, 2022).

JUSTIFICATION FOR THE QUALITATIVE CASE STUDY METHOD

A qualitative case study method is instrumental for several reasons. First, it allows for a comprehensive examination of the leadership strategies and sustainability practices within pharmaceutical companies, situated within their specific operational and regulatory environments. This approach acknowledges the unique contexts of each company, recognizing the influence of corporate culture, regulatory frameworks, and market pressures on sustainability practices (Barbieri da Rosa et. al, 2022).

Second, the case study design is inherently flexible, accommodating a variety of data sources — from interviews with industry leaders and sustainability officers to company reports and regulatory documents. This multimodal data collection strategy enriches the analysis, providing a multifaceted view of the challenges and strategies

employed to integrate sustainability into pharmaceutical operations (Dai, Chan, and Yee, 2018).

Third, this approach supports the investigation of complex, interrelated issues by focusing on selected instances where leadership and sustainability intersect within the industry. By delving deep into a few carefully chosen cases, this design enables a nuanced understanding of the dynamics at play, including the internal and external factors that facilitate or hinder the adoption of sustainable practices (Baumgartner, 2009).

Selection of Cases

Pharmaceutical companies committed to environmental sustainability will be selected using a purposive sampling strategy, considering factors like size, market reach, sustainability initiatives, and regulatory challenges. This diverse set of cases will provide a comprehensive understanding of the industry's sustainability efforts.

3.5 DATA COLLECTION METHODS

Data will be collected through semi-structured interviews with key stakeholders, analysis of company sustainability reports, and review of relevant regulatory and policy documents. Interviews will focus on extracting detailed insights into leadership strategies, sustainability initiatives, challenges encountered, and the impact of regulatory environments.

3.6 DATA ANALYSIS

Data analysis will follow an iterative process, employing thematic analysis to identify patterns, themes, and insights across the case studies. This approach will facilitate the examination of leadership roles and strategies, the integration of sustainability into corporate practices, and the navigation of regulatory landscapes. Through this detailed analysis, the study aims to uncover the factors contributing to successful sustainability practices and identify the barriers that must be overcome.

3.7 ETHICAL CONSIDERATIONS

This research design incorporates stringent ethical considerations, ensuring confidentiality and informed consent for all participants. Ethical approval will be sought from the relevant institutional review board, with all data treated with the utmost sensitivity and respect for participant privacy.

3.8 DATA COLLECTION

Semi-Structured Interviews

Semi-structured interviews will be conducted with key stakeholders in the pharmaceutical industry, including executives, managers, and sustainability officers. The interview guide will include open-ended questions on the following themes:

- International pharmaceutical businesses are becoming more proactive in their environmental management, and Berry and Rondinelli (2000) highlight how these corporations are being pushed by global forces to make larger commitments to sustainability and environmental improvement.
- Milanesi et al. (2020) examine sustainability in the pharmaceutical sector, emphasizing issues like water conservation, waste recycling, and more environmentally friendly production techniques (Milanesi, Runfola, & Guercini, 2020).
- In Shashi (2022), the importance of sustainability in the pharmaceutical supply chain is examined, and important tactics for putting sustainability-related tactics into practice are identified (Shashi, 2022)
- Kümmerer's (2008) research offers valuable perspectives on diverse approaches to mitigate environmental effects, specifically with the introduction of drugs into aquatic environments.
- The influence of planning, organizational, and communication techniques on sustainable development is examined by Ahmed et al. (2021) as they look at proactive environmental measures in the pharmaceutical business of Asian economies (Ahmed et. al, 2021).
- The significance of leadership style in the long-term viability of cognitive pharmaceutical services and its influence on the introduction of new services is explored by Kaae et al. (2011).

Participant Selection

Participants will be purposively selected to represent a wide range of perspectives within the pharmaceutical industry, including small to large enterprises and companies with varying degrees of commitment to sustainability. Approximately 10 to 12 interviews are planned, with the final number determined by data saturation.

Interview would last around 30 to 40 minutes Most questions will be open-ended, allowing participants ample time to share their personal experiences. The participants' responses will be manually transcribed during the interview because the auto-transcriber will make errors. Recordings will be reviewed to ensure that nothing gets missed.

3.9 DATA ANALYSIS

Thematic analysis will be employed in the examination of the interview data, adhering to Braun and Clarke's outlined six-step process (Kiger et. al, 2020). This process encompasses getting acquainted with the data, generating initial codes, identifying themes, refining these themes, defining and labeling the themes, and finally, compiling the report. This approach aids in uncovering patterns and themes within the data related to leadership roles, challenges, and practices in environmental sustainability within the pharmaceutical industry.

3.10 ETHICAL CONSIDERATIONS

Participants will receive an information sheet that explains the study's objectives, outlines their rights, and details the measures in place to ensure their confidentiality as per Institutional Review Board, Informed consent will be obtained from all participants.

The following questions are:

Sub-Question 1: What are the key leadership roles in pharmaceutical companies and strategies that influence the development and implementation of environmentally sustainable products?

1. Vision for Sustainability: "Can you describe your vision for integrating sustainability into your company's products and operations? How does this vision align with your leadership role and the company's overall strategy?"
2. What are the lessons learned from existing examples of pharmaceutical companies that have successfully implemented sustainable practices?
3. What are the future trends and challenges that the pharmaceutical industry will face in balancing environmental sustainability with financial success?

Sub-Question 2: What are the main challenges faced by pharmaceutical companies in integrating environmental sustainability into their operations, supply chain, and product development processes?

1. Product Innovation: "What challenges and opportunities do you encounter in developing and marketing environmentally friendly pharmaceutical products?"
2. What are the internal and external factors that may hinder or facilitate the adoption of sustainable practices within pharmaceutical companies?
3. Supply Chain Management: "In what ways are you working to enhance the sustainability of your supply chain? How do you measure and ensure compliance with environmental standards among your suppliers?"
4. Environmental Impact Measurement: "How does your company measure the environmental impact of its products and operations? Are these measurements integrated into your decision-making processes?"
5. Overcoming Resistance: "What resistance, if any, have you faced within your organization regarding the adoption of sustainable practices, and how have you addressed it?"

Sub-Question 3: What methods and standards are used by pharmaceutical companies for measuring and reporting the environmental impact of their products, and how does leadership ensure transparency and accountability in this process?

1. Navigating Regulations: "How do regulatory frameworks influence your approach to sustainability in product development and supply chain management? Can you provide examples of how you've adapted to these regulations?"
2. Implementing Sustainable Practices: "Could you elaborate on the sustainable practices your company has adopted in recent years? What motivated these changes, and what impact have they had?"
3. Financial Strains and Research Obstacles: "How do you balance financial strains and research obstacles with the need to invest in sustainable product development?"
4. Ethical and Social Accountability: "Can you speak about the ethical considerations and social accountability measures that guide your leadership in developing sustainable pharmaceutical products?"

3.11 CONCLUSION

This chapter has outlined a qualitative research methodology centered on semi-structured interviews to explore the complexities of leadership, challenges, and sustainability practices in the pharmaceutical industry. This approach is designed to yield rich, detailed insights into the strategies and challenges of promoting environmental sustainability within the sector. The findings from this qualitative inquiry are expected to contribute significantly to understanding how the pharmaceutical industry can navigate the challenges and opportunities of sustainability.

This methodology focuses on capturing the depth and nuances of pharmaceutical industry leaders' experiences and strategies in fostering environmental sustainability, thus providing comprehensive insights into the multifaceted challenges and opportunities in the field.

CHAPTER 4 - FINDINGS AND ANALYSIS

4.1 INTRODUCTION

This chapter delves into the pivotal role of leadership and strategic decision-making in driving sustainability within the pharmaceutical industry. Derived from primary research conducted in April 2024, this analysis encompasses insights from ten full-time, permanent leaders and two executives who shared their perspectives through a podcast. These industry leaders, representing a gender-diverse group from various pharmaceutical giants, offer a unique lens on the integration of sustainability into corporate practices.

The abbreviations in Table 1 represent ten participants and one more participant compiled from two members from podcast as Participant K identified by gender Female and Male. Experience level of seniority is presented as in decreasing order from seniority- dark green and ascending light green ≤5, ≤10, ≤ 15, ≤35 experience in years

	A	B	C	D	E
1	**Participant**	**Job Title**	**Experience**	**Gender**	**Interview Date**
2	A	CEO	10 plus years	Male	2024-04-23
3	B	Director - Strategy, Business Transformation and M&A	25 plus years	Male	14-04-2024
4	D	Fellow and Director	35 plus years	Male	04-04-2024
5	E	Senior Scientist	10 plus years	Female	2024-04-23
6	F	Senior Manager	5 plus years	Male	25-04-2024
7	G	Regulatory Affairs Associate	5 plus years	Female	20-04-2024
8	H	Bioassay Analyst	5 plus years	Female	2024-04-22
9	I	Scientific Officer	5 plus years	Male	16-04-2024
10	J	Quality Management System Administrator	5 plus years	Male	17-04-2024
11	K	Associate and Fellowship Scientist	15 plus years	Male	20-04-2024

Figure 1 - Participants' Background Information and Interview Calendar



Figure 2: Interview Timeline



Figure 3: Gender Breakdown by Experience

4.2- SUMMARY OF FINDINGS

The research examines how pharmaceutical sector leaders conceptualise and incorporate sustainability principles into their strategic operations, focusing on five critical themes to explore various aspects of sustainability.

1. **Leadership vision and strategic alignment for sustainability**: This theme examines how sustainability visions are integrated into corporate strategy, highlighting successful examples of companies that have successfully implemented these initiatives.
2. **Challenges and opportunities in sustainable product innovation**: The thesis discusses the challenges and opportunities pharmaceutical companies face in developing and marketing environmentally sustainable products, including strategies to improve sustainability in the supply chain.
3. **Measuring and managing environmental impact**: This theme delves into the methodologies and standards employed by companies to assess and manage the environmental impact of their operations and how these metrics influence corporate decision-making.
4. **Regulatory navigation and sustainable practice implementation**: It explores how companies navigate regulatory frameworks to implement sustainable practices effectively within their operations and product development processes.
5. **Balancing financial viability with environmental sustainability**: Finally, this theme addresses the financial and ethical considerations necessary for the adoption of sustainable practices, highlighting the challenges and future trends in balancing environmental stewardship with financial performance.

This chapter explores leadership in pharmaceutical companies' strategies and challenges in balancing environmental sustainability and business operations, providing insights to enhance understanding and promote sustainable practices.

4.3 LEADERSHIP VISION TO SUSTAINABILITY AND STRATEGIC IMPLEMENTATION OF SUSTAINABILITY

Participant A emphasizes sustainability in core strategies, aiming for global standard alignment and proactive environmental responsibility. Senior leaders set measurable objectives, influencing all business aspects. "Our main vision... is to increase medication adherence globally while integrating sustainable practices like

using recyclable plastics in our products. Further, discusses the use of biodegradable materials in product packaging and device recycling programs. This approach reduces waste and encourages circular economic principles within the industry. We aim to be the world’s leading medication adherence provider... We want to integrate the use of recyclable plastics and consider the full lifecycle of our products."

From Participant J “Leadership in the pharmaceutical sector is not merely about advocacy; it involves a tangible, active role in integrating sustainability throughout the company's DNA.”

Participant A is implementing sustainability measures throughout the pharmaceutical product lifecycle, focusing on reducing environmental impacts through packaging, formulations, and disposal mechanisms, aligning with the UN Sustainable Development Goals.

As noted by Participant D, Sustainability is transforming operational strategies, employee behaviors, and corporate ethos, influencing employee behaviors and incorporating sustainable practices into products and marketing strategies.

Described by Participant B, companies implement practices that reduce carbon footprints and enhance energy efficiency, showing a holistic approach that impacts various operational facets. Leaders believe in minimalistic

Participant B "We follow four pillars of sustainability... including sustainable purchasing, processing, innovation, and action within the community reflects the balance. Each component of our operations, from procurement to waste management, aligns with our sustainability pillars. From Procurement to Product Development, we have structured our supply chain to minimize environmental impact." Pharmaceutical companies are leveraging technology to achieve sustainability goals, resulting in more efficient drug formulations, reduced manufacturing waste, and improved supply chain transparency.

Participant J “a challenge on its own like because we are a business that we only spend money we don't make money like you know a research and development team doesn't make money straight away like the products that we work with really make money in the next 10 years' time like so you know you're investing money into that.”

Participant A talks about “we use ABS 920 grade plastic which is a medical grade plastic so if you don't want to use this plastic let's say plastic is torn apart so you can reuse and reheat this plastic which is an ABS plastic this is very little environment

friendly compared to the plastic based we use on a regular day-to-day basis so that's a basic two trends that we see we are trying to contribute currently on the one way which is a using less one-time plastic”

Participant K: “the commitment to sustainability is deeply integrated within our research and development processes, reflecting a meticulous and strategic alignment with our broader environmental goals, such as the 2030 project aimed at enhancing environmental friendliness. Our waste management system separates recyclables, metals, and regular waste, minimizing environmental impact. Our laboratories track equipment usage and expiration, promoting reuse and efficient resource management.”

4.4 CHALLENGES AND OPPORTUNITIES IN SUSTAINABLE PRODUCT INNOVATION:

Participant I: “Cost implications, technological limitations, and resistance within organizations regulatory pressures, market competition, and supply chain complexities are common challenges. The challenge is immense in industries driven by innovation and competition, where sometimes sustainability takes a backseat to market demands and rapid development cycles."

Participant H stated that, "Balancing sustainability with profit-making is challenging... especially when innovation and market demands push towards quicker, less sustainable solutions."

Participant J outlines “the tension between sustainability and profitability, highlighting the internal struggle Internally, the need to align all departments and manage costs without impacting product quality is a significant hurdle. stringent regulatory environments and varying global standards on sustainability. to maintain market competitiveness while adhering to environmental goals. Even stating the theme of brain drain addresses the challenge of retaining skilled professionals within a company, Brain drain as a critical challenge in retaining skilled employees, exacerbated by geographic and industry factors, impacting corporate innovation and competitiveness.”

Participant B discusses the company's proactive approach to creating sustainable products that offer benefits without compromising efficacy, indicating a focus on both incremental and breakthrough innovations.

Participant F stated, “Artificial intelligence and data analytics are transforming drug development, reducing environmental impact and driving innovation in the pharmaceutical industry, promoting sustainability throughout the production lifecycle.” Whereas Participant A said, “Smart technologies in medical devices enhance patient compliance and promote sustainability, influencing pharmaceutical companies' corporate culture and employee behaviors.”

Participant D stated “companies do not merely implement sustainable practices but cultivate a culture where sustainability is a shared value, influencing daily decisions and long-term planning.” Participant C continues “They are using digital platforms and social media to report on sustainability initiatives, including carbon emissions reductions and recyclable packaging. Life cycle assessment tools help identify areas for improvement and develop environmentally friendly products. Pharmaceutical companies are upgrading facilities to meet regulatory standards, setting new environmental performance benchmarks.”

Participant A highlights “if you have a social impact startup or government funds you if you have impact in particular field so that kind of innovation those kind of programs helps such startups or such companies”

Participant E, “Advanced manufacturing processes improve operational efficiencies, reduce waste, and reduce environmental impact. This shift towards minimal environmental impact benefits businesses.”

Participant E's approach to implementing virtual trials and electronic documentation reduces the carbon footprint associated with clinical trials, enhancing accessibility and compliance.

Participant D, “We are investing in emerging technologies to reduce our environmental footprint. This includes exploring alternatives to traditional sterilization methods that are less harmful to the environment, the shift towards reducing reliance on ethylene oxide for sterilization in favor of more sustainable alternatives exemplifies how companies are preparing for future environmental regulations.”

Participant C, “Pharmaceutical companies are embracing regulatory changes, exploring alternatives to ethylene oxide sterilization, and focusing on sustainable sterilization technologies like electron beam radiation.”

For Participant B “Biochemical oxygen demand (BODs), chemical oxygen demand (CODs), water leakages, and landfills are all significant factors that companies must consider when reducing their products. For example, companies

have started reducing sulfur oxides (Sox) into air through de-nitrogenation and de-sulfurization methodologies. For example, a child food product with a limited proportion of vanillin, which is a chemical, was sold in China due to changes in the method of calculating vanillin. A crisis management meeting was held to determine how to address this issue and find ways to reduce vanillin levels. The company's adoption of sustainable practices has driven significant changes and positively impacted its operations."

Participant K, "We consistently explore alternative chemical usage in product development, considering environmental impacts and cost. Our procurement processes prioritize quality and consistency, engaging approved vendors based on material quality and alignment with environmental objectives."

4.5 MEASURING AND MANAGING ENVIRONMENTAL IMPACT:

Participant G represented that, "reduce environmental impacts through cleaner production methods, which contribute to public health by reducing emissions and pollutants. This strategic alignment not only fulfills corporate sustainability goals but also supports global efforts like the United Nations Sustainable Development Goals (SDGs) Sustainability is driving innovation in the pharmaceutical industry by encouraging the development of new formulations and delivery mechanisms that reduce environmental impact while enhancing patient compliance and outcomes."

Participant H stated that, "Pharmaceutical companies prioritize ethical sustainability strategies, ensuring equitable access to medications, reducing health disparities, and committing to ethical sourcing and production practices."

Participant B's strategies reflect a balance between global sustainability pillars and local needs, ensuring relevant and effective practices across markets.

Participant K, "a robust, leadership-driven commitment to sustainability, strategically integrating eco-friendly innovations at every level of operation to influence both internal processes and the broader industry standards."

4.6 REGULATORY NAVIGATION AND SUSTAINABLE PRACTICE IMPLEMENTATION:

Participant D stated about, "companies are utilizing forums and workshops to engage stakeholders, fostering transparency and collaboration. This approach helps refine strategies, build trust, and address sustainability challenges. Risk assessments

now consider climate change, resource scarcity, and environmental compliance, affecting supply chain stability, production capabilities, and market access."

Participant C mentions that executives are responsible not just for profits but also for meeting specific sustainability goals, integrating these objectives into the company's core governance frameworks.

Participant A highlights the importance of partnerships with other companies and organizations to improve product sustainability, highlighting the benefits of research into alternative substances and advanced manufacturing technologies, resulting in cost savings and improved product efficacy.

Participant I reveal how regulatory changes are anticipated and incorporated into strategic planning, ensuring that the company remains compliant and competitive as standards evolve.

4.7 BALANCING FINANCIAL VIABILITY WITH ENVIRONMENTAL SUSTAINABILITY:

Participant B talked about "Investments in green chemistry biorefining is when you do the processing, and sustainable facilities boost local economies and reduce environmental impacts, as indicated by broader economic sustainability efforts. By integrating sustainability into their core strategies, pharmaceutical companies contribute to economic sustainability. For example, the construction of energy-efficient facilities often requires skilled labor and creates new jobs, while also contributing to the economic vitality of the communities where these facilities are located."

Participant C: "We measure our environmental impact by tracking water usage, energy consumption, and waste management... aiming for zero landfill." Detailed metrics and clear goals like zero landfill demonstrate Participant C commitment to accountability and transparency in its sustainability efforts.

Participant D: The company effectively incorporates stakeholder feedback into its sustainability strategies, focusing on community involvement and customer expectations regarding environmental responsibility.

Participant J: the concept of sustainable action involves community engagement and education, showcasing how companies are taking a broader role in promoting environmental health.

Participant G mentions goals set for 2030, illustrating a long-term vision that influences current actions and strategies, ensuring that sustainability is not just a temporary focus but a permanent fixture in their operational philosophy.

Participant A illustrates how adopting sustainable practices—like using biodegradable materials—can enhance market appeal and customer loyalty, ultimately increasing stakeholder value.

Participant F indicates that companies actively publicizing their sustainability efforts and engaging with the community positively affect their reputation, helping them stand out in a competitive market.

As per Participant B companies adopt sustainable practices like zero liquid discharge (ZLD) by anticipating future regulatory requirements and investing in research and development. Despite initial higher costs and commercial challenges, these proactive measures position them strategically and competitively, highlighting the advantage of early compliance with sustainability standards.

4.8 CONCLUSION

The pharmaceutical industry is actively addressing sustainability through strategic planning, stakeholder engagement, and innovative practices. Despite challenges, these companies align their efforts with global initiatives and local adaptations. Their approach not only meets regulatory and market demands but also anticipates future challenges, positioning them as a leader in sustainability and corporateresponsibility.

Figure 4: Graphical Representation (via Edwordle.net)

CHAPTER 5 – DISCUSSION

5.1 INTRODUCTION INTERPRETATION AND EXPLANATION OF RESULTS

This thesis discusses the crucial role of pharmaceutical leaders in promoting environmentally sustainable practices within the pharmaceutical industry, highlighting the sector's significant environmental impact., as highlighted by Archer et al. (2017). The critical role of ethical leadership in shaping workplace culture towards sustainability (Mo et. al, 2017) aligns with the theoretical arguments that leaders must inspire and enforce a culture of sustainability.

The chapter discusses the role of leadership and strategic decision-making in integrating sustainability into the pharmaceutical industry, focusing on challenges, environmental impact management, regulatory navigation, and financial considerations.

1. **Leadership vision and strategic alignment for sustainability**
2. **Challenges and opportunities in sustainable product innovation**
3. **Measuring and managing environmental impact**
4. **Regulatory navigation and sustainable practice implementation**
5. **Balancing financial viability with environmental sustainability**

5.2 LEADERSHIP VISION AND STRATEGIC ALIGNMENT FOR SUSTAINABILITY - CONTRAST BETWEEN EXPECTED AND ACTUAL RESULTS

The research identified various leadership styles within the pharmaceutical industry, each contributing differently to fostering an environment conducive to sustainability. Hui Li et al. (2019) found that transformational leadership, while visionary, is often necessary to navigate the complex pharmaceutical industry's rapidly changing landscape. This contrast indicates that no single leadership style is sufficient, but a dynamic and adaptive approach is required to effectively promote sustainability within the industry.

The sentiments expressed by Jones et al. (2023) and Kumar et al. (2018) about the necessity for pharmaceutical industry leaders to adjust business approaches to meet consumer expectations and implement Green Supply Chain (GSC) practices align with several participants' statements from the provided transcripts:

(Participant J) The report highlighted the significant role of leadership in integrating sustainability into a company's DNA, stating that leaders set metrics and

participate in sustainability forums to adjust business approaches. **(Participant B)** The discussion emphasized the importance of reducing carbon footprints and enhancing energy efficiency through Green Supply Chain practices, demonstrating leadership's commitment to sustainability. **(Participant D)** Sustainability impacts employee behaviors and corporate ethos, promoting cultural integration and meeting consumer expectations. Participants' commitment to sustainable practices aligns with Jones et al. (2023) study.

Sundgren et al. (2002) and Khan et al. (2014) both emphasize the importance of leaders providing a clear vision and setting strategic objectives for the future. **(Participant A)** Senior leaders set clear sustainability objectives, aligning with global standards and promoting proactive environmental responsibility, demonstrating a top-down commitment to align with goals and brand reputation. **(Participant J)** Leaders in the pharmaceutical sector advocate for sustainability, integrate it into company operations, and provide direction, setting strategic objectives and managing delivery to achieve common goals.

The concept of leaders managing change within organisations, as discussed by Cockburn et al. (2004), aligns with statements made by **(Participant J)** The leader's role involves managing significant organizational transitions, addressing challenges, and minimising resistance to maintain team continuity and morale during the transition from research to on-market business. **(Participant H)** The text highlights the importance of leadership in balancing sustainability with profitability, managing change, and maintaining high morale while navigating business model adjustments and innovation pressures.

The principles of leadership involving informed decision-making under pressure, as described by Vuorenkoski et al. (2008), resonate with the statements made by **(Participant G)** The discussion emphasized the importance of strategic alignment with global sustainability goals, highlighting the need for cleaner production methods and informed decision-making for environmental, public health, and stakeholder benefits.

The concept of leaders playing a crucial role in the development of team members, as discussed by Cockburn et al. (2004), aligns with statements made by **(Participant D)** Companies foster a culture of sustainability through strategic thinking and emotional intelligence in leadership, promoting social capital, problem-solving,

and innovation, fostering team development and individual performance improvement. **(Participant E)** The study emphasizes the importance of leadership in guiding team members to adopt sustainable practices and comply with regulatory changes, thereby enhancing professional development.

The notion of democratic leadership, characterized by seeking input from team members and stakeholders to foster a collaborative environment, as described by Foels et al. (2000), aligns well with insights shared by **(Participant F)** The study highlights the use of virtual trials and electronic documentation in the pharmaceutical industry to reduce carbon footprints and improve compliance, demonstrating the effectiveness of democratic leadership.

The concept of servant leadership, which prioritizes the growth and well-being of team members and communities, as described by Allen et al. (2016), closely aligns with the insights provided by **(Participant B)** The discussion emphasised the importance of sustainability practices, promoting a servant leadership style that balances global and local needs, fostering employee engagement and loyalty. **(Participant D)** Sustainability is integral to corporate culture, promoting servant leadership, enhancing employee engagement and retention, especially in the pharmaceutical industry, whose impact on public health is critical.

Ahmed et al. (2016) highlights the relevance of autocratic leadership in certain aspects of the pharmaceutical industry despite its less emphasis in modern collaborative settings. This leadership style, focusing on unilateral decision-making by leaders, particularly in high-stakes areas requiring quick decisions or strict compliance, aligns with the insights shared by **(Participant J)** The research and development department faces funding challenges, necessitating a shift to on-market business, necessitating autocratic leadership for stability and continuity. **(Participant H)** Autocratic leadership is often used in pharmaceutical settings to resolve conflicts and enforce compliance with corporate strategies and regulatory requirements, particularly in manufacturing and quality control, despite its less prevalence in modern settings. Situational leadership, as proposed by Butler et al. (2013), involves adapting leadership styles to meet specific tasks, team needs, and challenges, demonstrating flexibility in response to evolving industry standards and global sustainability goals. **(Participant J)** Leadership involves participating in sustainability forums, attending conferences, and aligning initiatives with business goals, demonstrating a situational approach that adapts to regulatory changes and market dynamics. **(Participant D)**

Sustainability influences employee behaviors and corporate ethos, requiring situational leadership to adapt methods to internal and external pressures. Leaders must be versatile in dynamic industries.

Ahmed et al. (2021) emphasise the need for further exploration into green practices in production and supply chain processes, as well as the development of environmentally friendly drugs. Participant k's pharmaceutical industry is demonstrating sustainability leadership through R and D processes, waste management, equipment usage, and strategic vendor engagement, setting industry standards and promoting sustainable consumer behavior (Hayler et al. 2018 and Bagheri et al. 2017)

5.3 CHALLENGES AND OPPORTUNITIES IN SUSTAINABLE PRODUCT INNOVATION

The findings about consumer preferences shifting towards environmentally sustainable products (Royne et al., 2011; Kumar et al., 2018) The growing demand for eco-friendly products and corporate social responsibility are driving the implementation of Green Supply Chain practices, making sustainability efforts a competitive advantage for companies. **Participant I** and **H** The study highlights challenges in sustainable innovation, such as cost, technological limitations, and regulatory pressures, but also highlights opportunities for advancements in green chemistry and regulatory support.

The Hayler et al. (2018) study highlights the potential for sustainable metal catalysis in the pharmaceutical industry, highlighting the need for eco-friendly methods in drug production to minimize environmental impact while maintaining product efficacy.

Participant H's The tension between profitability and sustainability is driving innovation in sustainable practices, such as leveraging AI and advanced manufacturing technologies. Leader development is crucial for creating an environment conducive to innovation and effective problem-solving (2000).

The focus on overcoming challenges in new product development by adapting research and development processes to align with current technological and market trends, as discussed by Marques et al. (2019), closely aligns with the insights and initiatives of several participants (**Participant J)** The participant highlighted the need for leaders to be adaptive and forward-thinking in navigating technological and market

demands to drive innovation in product development. **(Participant F)** The text discusses the use of artificial intelligence and data analytics in drug development, highlighting its modernisation and leadership in enhancing product development outcomes.

5.4 MEASURING AND MANAGING ENVIRONMENTAL IMPACT

The pharmaceutical industry is adopting cleaner production methods, reducing solvent use, enhancing energy efficiency, and innovating waste management to promote sustainability and comply with regulatory requirements, thereby fostering a culture of environmental responsibility as stated by Participant D.

Bouchard et al. (2012) highlight corruption in Uganda's healthcare sector, highlighting ethical leadership and integrity's relevance globally, including the Irish pharmaceutical industry, and the importance of these principles in practices. **(Participant H)** The participant emphasized the importance of balancing profitability with sustainable and ethical practices, highlighting the need for integrity in leadership, combating corruption, and ensuring equitable healthcare access. **(Participant G)** The text emphasizes the importance of integrating sustainability and ethical practices in business strategies, emphasizing the role of integrity in leadership, combating corruption, and improving healthcare access. **(Participant D)** The SHIFT Framework for Sustainable Behaviors emphasizes the importance of fostering an ethical corporate culture, addressing issues like corruption, and ensuring fair access to healthcare services, highlighting the role of social influence and habit formation in shaping sustainability behaviors., as discussed by White et al. (2019), aligns well with insights from **(Participant B)** The company is promoting sustainable habits through community action and four sustainability pillars, aligning with the SHIFT Framework principles to influence consumer behavior towards sustainable products.

5.5 REGULATORY NAVIGATION AND SUSTAINABLE PRACTICE IMPLEMENTATION

The study highlights the significance of navigating the complex regulatory landscape for sustainable practices, involving stakeholders, and the role of leadership in integrating sustainability goals into governance and crisis management. (Priporas et al. 2008) **(Participant B)** highlights the importance of effective crisis management

in China, emphasizing the need for swift decision-making and stakeholder communication to navigate new regulations and ensure minimal impact on operations.

The focus on adjusting to technological and regulatory shifts, and the need for leadership training to manage these changes effectively, as discussed by Megheirkouni et al. (2020), aligns well with the insights and initiatives of **(Participant G)** The discussion highlighted the importance of leadership adept at navigating both technological and regulatory landscapes, focusing on proactive adaptations to regulatory changes and digital platforms for environmental impact management.

The dissertation explores sustainability strategies in pharmaceutical companies, focusing on environmental contaminants management and waste management. It aligns with participants' insights, highlighting their commitment to environmental sustainability and practical implementations, enhancing understanding of their effectiveness and challenges.

5.6 BALANCING FINANCIAL VIABILITY WITH ENVIRONMENTAL SUSTAINABILITY

The pharmaceutical industry faces financial challenges while balancing environmental sustainability. Participant B stated that, Green chemistry investments reduce environmental impacts, boost local economies, and contribute to economic sustainability.

This balance is achieved through strategic investments in innovation and technology that improve operational efficiencies and reduce costs in the long run. Participant E highlights how the adoption of virtual trials and electronic documentation reduces the carbon footprint of clinical trials, demonstrating how sustainability can also lead to cost savings and enhanced operational efficiency. The study by Olivia et al. (2021) on the adoption of Continuous Improvement (CI) strategies like Lean Six Sigma in the Irish pharmaceutical sector highlights several challenges and integration efforts related to improving operational excellence. This focus on enhancing productivity and quality through CI methodologies **Participant E** the study emphasizes the use of advanced manufacturing processes to conserve energy, reduce waste, and enhance operational efficiency, incorporating lean methodology and aligning with O'Mahony et al (2015).'s findings on the Irish cost-effectiveness threshold.

Participant H - The speaker discusses the internal conflict between profitability and sustainable practices, highlighting leadership challenges in balancing financial viability with ethical and environmental considerations, reflecting the complex interplay between economics, healthcare policies, and leadership decisions as highlighted by O'Mahony et al.

Participant B - The participant highlighted the integration of sustainability into business operations, focusing on cost-effectiveness and rational rationing in healthcare, while reducing carbon footprints and enhancing energy efficiency, as discussed in the O'Mahony study. **Participant B** spoke about investments in green chemistry, biorefining, and sustainable facilities, which boost local economies and reduce environmental impacts. "By integrating sustainability into our core strategies, we contribute to economic sustainability, creating jobs and fostering economic growth through environmentally friendly innovations."

Participant I noted the significant challenges such as cost implications, technological limitations, regulatory pressures, market competition, and supply chain complexities. "Balancing sustainability with profit-making is challenging... especially when innovation and market demands push towards quicker, less sustainable solutions."

Participant J - The discussion emphasized the need for financial sustainability in business practices and the transitioning roles in the pharmaceutical industry, highlighting the economic implications of these decisions as mentioned by O'Mahony et al.

These participants illustrate how economic considerations, particularly cost-effectiveness, influence leadership decisions in the pharmaceutical sector, corresponding to the issues raised by O'Mahony et al. (2015).

5.7 LIMITATIONS

This thesis on the integration of environmental sustainability within the pharmaceutical industry acknowledges several inherent limitations characteristic of qualitative research. First, the research design precludes extensive hypothesis testing or large sample assessments, which might have offered a broader validation of the findings (Yu et al., 2021). The reliance on participant experiences and subjective perceptions, while providing depth, also introduces potential biases that could skew

the results (Dobrovolny and Fuentes, 2008; Vaughan, 2019). The semi-structured nature of the interviews, although rich in qualitative data, is time-intensive, limiting the number of participants to ten. This small sample size constrains the generalizability of the findings and suggests that different participant groups might provide alternative insights.

The research's geographical context was limited by limited academic resources, particularly those focusing on Irish-based employees and USA-based pilots, which were often repetitive or culturally specific.

Additionally, the focus on a specific age group (29-69 years old) may have excluded valuable perspectives from younger, early-career employees who could have differing challenges and insights regarding environmental sustainability practices in the workplace. This choice of demographic has inadvertently narrowed the scope of the study and its applicability to a broader workforce spectrum.

The research's limitations highlight challenges and suggest future research on sustainability practices in the pharmaceutical industry, particularly in regions with varying cultural and regulatory backgrounds. A restructured version is provided for future research.

5.8 FUTURE RESEARCH

This study highlights the complex relationship between environmental sustainability and pharmaceutical practices, suggesting a longitudinal study to compare global sustainability strategies and corporate culture shifts in the pharmaceutical industry over the next 12 months.

Focused research on specific demographic groups within the pharmaceutical sector—such as employees in various stages of their career, or differing levels of management—could reveal nuanced insights into the challenges and opportunities of implementing sustainable practices.

Such studies could explore whether certain groups are more adept at integrating sustainability into their daily operations or face unique obstacles. Employing a quantitative methodology could complement this study's qualitative

insights by providing statistical data on the prevalence and effectiveness of sustainable practices across a larger sample of pharmaceutical companies.

This approach could help in identifying broader trends and establishing benchmarks for sustainability in the industry. Examining the impact of remote work on sustainability efforts in the pharmaceutical industry from an international perspective could yield valuable comparisons and best practices. Using frameworks like Hofstede's cultural dimensions could uncover how cultural differences influence the adoption and success of sustainable practices.

The study suggests that understanding the employer's perspective on sustainability's impact on business outcomes, such as productivity and talent retention, and the actual benefits of sustainability initiatives, such as remote work flexibility, could enhance research on environmental responsibilities in the pharmaceutical industry.

5.9 CONCLUSION

This research highlights the importance of sustainability in the pharmaceutical industry, highlighting the need for effective leadership to embed sustainability into every aspect of business operations. Pharmaceutical leaders align their operations with global sustainability goals and local needs, not only meeting regulatory demands but also setting a proactive agenda to anticipate future challenges. This strategic foresight and commitment to sustainable practices demonstrate the industry's potential to lead in corporate responsibility, driving innovations that benefit both the environment and long-term business viability.

CHAPTER 6 - CONCLUSION AND RECOMMENDATIONS

This chapter synthesizes the findings from the study, first addressing the sub-questions and then tackling the main research question. It ends with four recommendations and several concluding observations for consideration.

6.1 RESEARCH QUESTIONS & FINDINGS

The study investigates leadership's role in promoting sustainability in the pharmaceutical industry, utilizing interviews and data to understand how it influences the integration of sustainable practices into corporate strategies. This shift saw organizations such as Johnson & Johnson, Pfizer, Merck, and Roche in the 2030 project highlighted by Ahmed et al. (2021).

The PESTLE analysis enhances the literature review on sustainability in the pharmaceutical industry by linking macro-environmental factors to industry-specific challenges and strategies, improving research quality and applicability (Evans et al., 2015), (Berry et al., 2000), (Anand et al., 2019), (Kaae et al., 2011), (Katz et al., 2022), (Hu et al., 2023). After conducting the interview and a podcast brings one question that, "How can pharmaceutical leaders harness emerging technologies not only to improve environmental sustainability but also to enhance transparency and ethical practices in global supply chains?"

Sub-Question 1: What are the key leadership roles in pharmaceutical companies and strategies that influence the development and implementation of environmentally sustainable products?

The company is promoting green chemistry, sustainable sourcing, and technology investment to reduce carbon footprints and enhance energy efficiency, aligning with global standards and environmental responsibility. Participant K discussed the use of radioactive and green bins for environmental purposes, emphasizing the importance of sourcing sustainable vendors and proper labeling for alignment with United Nations Sustainable Development Goals.

Leadership Roles and Strategies:

- Visionary Leadership: Pharmaceutical leaders are key in integrating environmental sustainability into the company's strategy, influencing product

development and supply chain management, ensuring alignment with strategic goals.

- Strategic Implementation: Leadership is crucial in implementing sustainable strategies, such as reducing carbon footprints, enhancing energy efficiency, and innovating product packaging, to drive business operations.
- Engaging Stakeholders: Leaders involve stakeholders like employees, consumers, regulators, and the community to support sustainability initiatives, refining strategies, and building trust and collaboration across the industry
- Promoting Innovation: Leaders promote innovation by investing in environmentally friendly products, reducing environmental impacts, and enhancing sustainability in research and development.
- Cultural Integration: Leadership in pharmaceutical companies is crucial for cultivating a culture of sustainability, influencing employee behaviors and decision-making at all levels for long-term sustainability.

Sub-Question 2: What are the main challenges faced by pharmaceutical companies in integrating environmental sustainability into their operations, supply chain, and product development processes?

Participants I and H The discussion delved into the challenges of integrating environmental sustainability into pharmaceutical operations, including the high costs and investment required for sustainable technologies and process redesign.

- Complex Supply Chains: The global and layered nature of pharmaceutical supply chains makes ensuring sustainable practices at every level difficult, especially when dealing with suppliers from countries with less stringent environmental regulations.
- Technological Barriers: Integrating new, cleaner technologies can be challenging due to technical obstacles, resistance to change within organizations, or a lack of skilled workforce.
- Balancing Sustainability with Product Efficacy and Safety: It's crucial that sustainability efforts do not compromise the effectiveness or safety of pharmaceutical products, which can restrict the options for using sustainable materials or processes.

- Market Competition and Consumer Perceptions: Pharmaceutical companies face challenges in managing sustainability costs, maintaining price competitiveness, and effectively communicating the value of sustainable products to consumers who prioritize efficacy or brand reputation.
- Intellectual Property Issues: Developing new sustainable processes can involve complex IP challenges, such as securing patents or ensuring freedom to operate.
- Cultural and Organizational Change: Prioritizing sustainability requires a cultural shift within the company, demanding leadership commitment and widespread employee engagement.
- Measuring and Reporting Sustainability: Developing reliable metrics for sustainability and reporting them in a transparent manner is complex and requires balancing detail with practical data collection.
- Resource Limitations: Limited sustainable materials hinder full integration, requiring strategic innovation, stakeholder engagement, and robust management. Pharmaceutical companies can achieve environmental benefits, operational efficiency, and stakeholder trust.

The company is addressing complex challenges in the pharmaceutical industry by leveraging strategic opportunities and integrating sustainable practices into all operations and decision-making processes:

Challenges in sustainability integration:

- Regulatory Compliance: Compliance with environmental laws and regulations requires a robust framework and continuous adjustments to operations and strategies, despite the complexity and varying global regulatory landscapes.
- Cost Implications: Integrating sustainable practices requires substantial initial investment, including green technology, materials, and process redesigns, balancing these costs with profitability and maintaining competitive pricing is a significant challenge.
- Technological Limitations: The implementation of sustainable practices can be hindered by current technology limitations or the high costs of cutting-edge technologies.
- Supply Chain Complexities: The global supply chain faces challenges in sustainability due to diverse supplier practices and standards, necessitating coordination and monitoring for consistency and compliance.

- Market Competition and Consumer Preferences: Pharmaceutical companies face the constant challenge of balancing market demands and consumer sustainability expectations, requiring continuous innovation to create sustainable and consumer-friendly products.
- Internal Resistance: Strong leadership is crucial to overcome internal resistance and organizational inertia, promoting a company-wide embrace of sustainability initiatives and overcoming internal barriers.

Sub-Question 3: What methods and standards are used by pharmaceutical companies for measuring and reporting the environmental impact of their products, and how does leadership ensure transparency and accountability in this process?

Methods and Standards for Measuring Environmental Impact:

Pharmaceutical companies use Life Cycle Assessment (LCA) to assess their environmental impact, quantifying greenhouse gas emissions and water footprints. They also use Carbon Footprint Analysis to reduce emissions and water use. Energy consumption metrics help identify energy-intensive processes and waste management metrics to reduce waste generation. International standards like ISO 14001, GRI, and SDGs promote efficient resource use, waste reduction, and global impact.

Leadership's Role in Ensuring Transparency and Accountability:

- Setting Clear Policies and Goals: Leadership sets clear environmental policies and sustainability goals, committing to specific targets like reducing emissions and energy use, and publicly sharing these commitments to hold organizations accountable.
- Regular Reporting and Disclosure: Effective leaders regularly monitor and report environmental performance, ensuring transparency through annual sustainability reports or financial reporting integration, providing stakeholders with a clear view of the company's environmental impact.

- Stakeholder Engagement: Leaders engage stakeholders to gather feedback, build trust, and ensure environmental efforts align with global best practices and expectations.
- Internal Audits and Compliance Checks: Leadership enforces environmental policies and standards through rigorous internal audit procedures, which identify compliance issues and operational inefficiencies, promoting continuous improvement.

Primary Question: “How can pharmaceutical leaders harness emerging technologies not only to improve environmental sustainability but also to enhance transparency and ethical practices in global supply chains?”

The pharmaceutical company is committed to sustainability through rigorous regulatory frameworks, sustainable practices, strategic financial management, and strong ethical and social accountability.

- **Navigating Regulations**: The company has complied with EU regulations by modifying raw material sourcing strategies to promote safer, environmentally friendly alternatives, ensuring compliance and enhancing product sustainability.
- **Implementing Sustainable Practices**: Green chemistry, energy efficiency, and sustainable packaging are being implemented to reduce waste, meet global sustainability standards, and improve brand image, resulting in cost savings and reduced environmental liability.
- **Financial Strains and Research Obstacles**: The company manages financial burdens of sustainable R&D through partnerships, long-term cost-saving investments, and governmental incentives to balance high development costs against financial constraints.
- **Ethical and Social Accountability**: The company prioritizes ethical governance, focusing on transparency, stakeholder engagement, and ethical sourcing, supported by rigorous internal policies and CSR initiatives.

The company is integrating sustainability strategies to comply with regulations, enhance its global reputation, and utilize emerging technologies to improve environmental sustainability and ethical practices.

Here’s how they can leverage technology to address these crucial aspects:

1. **Blockchain Technology Application**: Blockchain technology enables transparent and tamper-proof record-keeping for every transaction in the supply chain, including raw material sourcing, manufacturing processes, distribution, and product disposal.

Benefits: Transparency and traceability in the supply chain ensure product authenticity and ethical sourcing, while anti-counterfeiting prevents counterfeit drugs from being distributed.

2. **Internet of Things (IoT) Application**: IoT devices can be integrated throughout the supply chain to monitor conditions in real-time, such as temperature control during drug transportation, which is critical for maintaining drug efficacy.

Benefits: Enhanced monitoring ensures safety standards in pharmaceutical storage and transit conditions, while alerts reduce spoilage and waste by detecting deviations in expected conditions.

3. **Artificial Intelligence (AI) and Machine Learning (ML) Application**: AI can analyze vast amounts of data to optimize supply chain operations, predict maintenance needs, and identify inefficiencies.

Benefits: Predictive Analytics enhances production schedule optimization by accurately forecasting demand, preventing overproduction and waste, and provides operational efficiency insights for efficient distribution routes and methods.

4. **Eco-friendly Packaging Innovations Application**: Utilizing advanced materials and designs to develop sustainable packaging solutions that reduce environmental impact.

Benefits: Companies can reduce their environmental footprint by using biodegradable or recyclable materials, which also enhances their brand image by demonstrating a commitment to sustainability.

5. **Geospatial Analytics Application**: Use of satellite and aerial imagery to monitor environmental compliance of suppliers and assess the impact of supply chain operations on ecosystems.

Benefits: Compliance Monitoring enables real-time environmental regulation oversight at remote production sites or suppliers, while Impact Assessment provides data on supply chain activities' local environmental impact for sustainability reporting and improvement measures.

To effectively implement these technologies, pharmaceutical leaders should:

- Invest in Skills Development: Train staff on new technologies to ensure they are effectively integrated and utilized.
- Partner with Tech Firms: Collaborate with technology providers to develop customized solutions that meet specific supply chain needs.
- Set Clear Objectives: Define specific sustainability and transparency goals to guide technology implementation.
- Ensure Data Security: As digital technologies often involve handling sensitive information, robust cybersecurity measures are essential.

Pharmaceutical companies can improve supply chain operations, environmental sustainability, and ethical practices by strategically applying technologies, addressing regulatory demands and building a strong brand reputation.

6.2 RECOMMENDATIONS

INTRODUCTION

This chapter provides strategic recommendations for enhancing sustainability in the pharmaceutical industry, guiding leaders, policymakers, and stakeholders to integrate environmental sustainability with corporate operations, based on interviews with key industry players.

1. Pharmaceutical companies should prioritize sustainability in their corporate strategies, adopt proactive regulatory compliance, engage in policy discussions, and conduct economic analyses to attract environmentally conscious consumers and differentiate themselves.

Timeframe:

- Short-Term (1-6 months) - Initial Planning and Commitment: Leaders need to outline their commitment, which includes setting up a sustainability task force or committee. This phase involves the initial audit of current practices and identifying areas for improvement.
- Medium-Term (6 months - 2 years) - Integration into Strategy: Embedding sustainability into the business strategy, which might include changing operational processes, product redesigns for environmental efficiency, or sourcing sustainable materials.

- Long-Term (2 years and beyond) - Ongoing Assessment and Reporting: Regular sustainability reporting to stakeholders, revising strategies based on feedback and evolving sustainability standards.

Cost Considerations:

- Initial Costs: These may include the expenses of sustainability audits, consultation fees, and initial investments in technology or infrastructure modifications.
- Operational Costs: There may be ongoing operational costs related to maintaining new systems or processes, such as higher raw materials costs for sustainable inputs or costs associated with achieving certifications like LEED or ISO 14001.

Additional Considerations:

- Return on Investment (ROI): While integrating sustainability can involve upfront costs, it can also lead to significant long-term savings and added value through enhanced brand reputation, increased customer loyalty, and potential tax incentives.
- Risk Management: Addressing sustainability can reduce regulatory and reputational risks and prepare the business for future regulations.
- Formalizing sustainability goals in a pharmaceutical company involves a multi-step process that is both time-consuming and resource-intensive. Here's how it could be structured:

2. Leadership Training and Development: Invest in sustainability training for all levels of management. Leaders must be equipped not only with a deep understanding of sustainability but also with the skills to implement these strategies effectively. This will empower them to drive change and foster a culture of sustainability within their organizations.

Timeframe:

- Short-Term (1-3 months) - Program Development involves creating a training curriculum tailored to the pharmaceutical industry, considering sustainability challenges and regulatory environments, selecting methods and materials.

- Medium-Term (3-6 months) - Pilot Training Sessions: Conducting initial training sessions with a select group of leaders to refine and adjust the approach based on feedback.
- Long-Term (6-12 months) - Full Implementation: Rolling out the training program across the organization, ensuring all management levels are covered.

Cost Considerations:

- Development Costs: These include costs for curriculum development, which may involve hiring sustainability consultants or training specialists familiar with the pharmaceutical sector.
- Delivery Costs: Depending on the mode of training (in-person, virtual, hybrid), costs can include trainer fees, technology setup for virtual training platforms, venue costs for in-person sessions, and travel expenses.
- Material Costs: Production of training materials, whether digital or physical. This includes handouts, access to online resources, and interactive tools.
- Operational Costs: Administrative costs associated with managing the training program, such as staff time, scheduling software, and participant management.
- Evaluation Costs: Expenses related to measuring the effectiveness of the training programs through surveys, feedback tools, and potentially third-party evaluation services.

Additional Considerations:

- ROI and Long-Term Benefits: While upfront costs might be significant, the long-term benefits of having a well-trained leadership team that can effectively implement and advocate for sustainability are considerable. These benefits can include improved compliance with regulations, enhanced company reputation, and increased employee engagement.
- Scalability and Flexibility: Costs can vary based on the scale of the training program and the flexibility required. For instance, creating scalable digital training modules might involve higher initial costs but can be more cost-effective in the long run.

3. Enhance Innovation and Sustainability in Product Development: Encourage greater investment in research and development focused on sustainable product innovation. This should include exploring new materials, production processes, and

waste management techniques that reduce environmental impacts. Implement cross-functional teams that include sustainability experts during the product design phase to ensure that products are developed with the best environmental practices in mind from the outset.

Timeframe:

- Short-Term (1-3 months) - Strategic Planning: Leaders set up strategic meetings to define the vision and objectives for integrating sustainability with innovation and regulatory navigation. This includes identifying key sustainability challenges that can be addressed through innovation.
- Medium-Term (3-12 months) - Team Formation and Training: Establish dedicated teams for sustainability innovation and regulatory affairs and invest in specialized training to enhance their expertise in these areas.
- Long-Term (1-3 years) - Full-Scale Implementation: Roll out successful initiatives across the company. This involves scaling up production, distributing resources, and fully integrating new practices into the business operations.

Cost Considerations:

- Strategic Planning and Expert Consultation Costs: Expenses related to engaging consultants who specialize in sustainability, innovation, and regulatory affairs.
- Team Building and Training Costs: Investments in recruiting or reallocating internal resources, and providing them with specialized training in sustainability practices, innovative technologies, and regulatory compliance.
- Research and Development Costs: Significant funding may be needed for R&D activities focused on developing new sustainable products or processes. This includes laboratory costs, prototype development, and pilot testing.
- Regulatory Navigation Costs: Costs associated with compliance, including registration fees, legal costs for ensuring alignment with sustainability regulations, and potentially lobbying or engaging with policymakers.
- Technology and Infrastructure Investment: Expenses for updating or purchasing new equipment and technology to support sustainable innovation.

Additional Considerations:

- Return on Investment (ROI): While the initial costs can be high, the potential for cost savings through operational efficiencies, reduced fines and penalties for non-compliance, and enhanced market positioning can provide substantial returns.

- Risk Management: Proactively engaging in innovation and regulatory navigation reduces the risk of non-compliance and enables the company to adapt to regulatory changes more swiftly.
- Brand Reputation and Competitive Advantage: Successfully leading in sustainability can significantly enhance a company's brand, attracting more customers and partners who prioritize environmental responsibility.

4. Improve Measurement and Management of Environmental Impact: Adopt more sophisticated life cycle assessment (LCA) tools and sustainability metrics to better understand and manage the environmental impact of products and operations. Increase transparency by publicly reporting on sustainability metrics and progress. This not only builds consumer trust but also holds the company accountable for its environmental impact.

Timeframe:

- Short-Term (1-3 months) - Initial Assessment and Planning: Identify key sustainability issues relevant to the pharmaceutical industry, such as waste management, energy use, water conservation, and ethical sourcing.
- Medium-Term (3-6 months) - Goal Setting: Define specific, measurable, achievable, relevant, and time-bound (SMART) sustainability goals based on the initial assessments and stakeholder feedback.
- Long-Term (6 months - 1 year and beyond) - Implementation: Begin executing sustainability initiatives outlined in the corporate strategy, such as reducing carbon footprint, improving packaging sustainability, or enhancing supply chain transparency.

Cost Considerations:

- Initial Costs: These might include costs for conducting environmental audits, sustainability consultancy fees, and expenses related to stakeholder engagement activities.
- Implementation Costs: Costs related to the adoption of new technologies, process changes, or infrastructure upgrades necessary to meet sustainability goals. This might also include the cost of obtaining certifications like ISO 14001 for environmental management systems.

Additional Considerations:

- ROI and Cost Savings: While initial costs may be substantial, implementing sustainable practices can lead to significant cost savings in the long run due to improved efficiency and reduced waste.
- Risk and Compliance Costs: Proactively adopting sustainability measures can mitigate risks related to non-compliance with environmental regulations, which might result in fines or reputational damage.

6.3 CONCLUSION

Despite challenges like regulatory hurdles, cost implications, technological limitations, and market competition, there are opportunities for innovation and differentiation. Recommendations include strengthening leadership commitment, navigating regulatory environments, balancing financial viability with sustainable practices, and enhancing product development innovation. The study emphasises the importance of a holistic approach to sustainability, including environmental, ethical, and social dimensions. This research study has successfully addressed its guiding questions, providing comprehensive insights into the topic. It aims to enhance the broader understanding of this subject and serve as a valuable resource for subsequent investigations.

Personal Learning Statement

Pursuing my Masters in International Business offered a unique intersection to explore sustainability in the pharmaceutical industry, a topic that aligns closely with both my academic pursuits and professional experiences. My profound interest in this area was piqued during my tenure as a researcher and further nurtured through various roles in the healthcare and biotechnology sectors. The pharmaceutical industry, pivotal in advancing healthcare, faces critical sustainability challenges, particularly in environmental impact and ethical practices, areas where I believe meaningful change can be driven through innovative management

The COVID-19 pandemic underscored the essential role of pharmaceuticals yet highlighted the pressing need for sustainable practices within the industry. As someone experienced in biotechnology with an understanding of genetic counselling and rare diseases, I recognized the importance of integrating sustainability into core

business strategies to ensure long-term environmental, economic, and social viability. My thesis explores how management can be leveraged to foster a culture of sustainability in pharmaceutical companies, aiming to align human capital management with sustainable development goals.

This focus not only reflects my commitment to blending life sciences expertise with business but also my dedication to contributing to a more sustainable future in an industry critical to global well-being.

CHAPTER 7 REFERENCES:

1. Abuhammad, S., 2022. Preparing for Future Pandemics: Challenges for Healthcare Leadership. *Journal of Healthcare Leadership*, 14, pp. 131 - 136. https://doi.org/10.2147/JHL.S363650.
2. Ahmed, L., Davis, A., & Schalkwyk, R., 2016. Leading and motivating pharmaceutical sales teams through a strategic alliance strategy.. *Journal of Contemporary Management*, 13, pp. 169-189.
3. Ahmed, R., Kyriakopoulos, G., Štreimikienė, D., & Streimikis, J., 2021. Drivers of Proactive Environmental Strategies: Evidence from the Pharmaceutical Industry of Asian Economies. Sustainability. https://doi.org/10.3390/su13169479.
4. Allen, G., Moore, W., Moser, L., Neill, K., Sambamoorthi, U., & Bell, H., 2016. The Role of Servant Leadership and Transformational Leadership in Academic Pharmacy. *American Journal of Pharmaceutical Education*, 80. https://doi.org/10.5688/ajpe807113.
5. Archer, E.., Petrie, Bruce., Kasprzyk-Hordern, B.., & Wolfaardt, G.. (2017). The fate of pharmaceuticals and personal care products (PPCPs), endocrine disrupting contaminants (EDCs), metabolites and illicit drugs in a WWTW and environmental waters.. *Chemosphere* , 174 , 437-446 . http://doi.org/10.1016/j.chemosphere.2017.01.101
6. Bagheri, S.., Termehyousefi, A.., & Do, Trong-On. (2017). Photocatalytic pathway toward degradation of environmental pharmaceutical pollutants: structure, kinetics and mechanism approach. *Catalysis Science & Technology* , 7 , 4548-4569 . http://doi.org/10.1039/C7CY00468K
7. Beek, T., Weber, F., Bergmann, A., Hickmann, S., Ebert, I., Hein, A., & Küster, A., 2016. Pharmaceuticals in the environment—Global occurrences and perspectives. *Environmental Toxicology and Chemistry*, 35. https://doi.org/10.1002/etc.3339.
8. Butler, J., & Reese, R., 2013. Leadership Style and Sales Performance: A Test of the Situational Leadership® Model. *Journal of Personal Selling and Sales Management*, 11, pp. 37-46. https://doi.org/10.1080/08853134.1991.10753877 .
9. Campbell, Benjamin, et al. “Consumer Perceptions of Eco-Friendly and Sustainable Terms.” *Agricultural and Resource Economics Review*, vol. 44, no. 1, Apr. 2015, pp. 21–34, https://doi.org/10.1017/s1068280500004603. Accessed 26 Oct. 2019.
10. Chemat, F.., Vian, Maryline Abert., Fabiano-Tixier, A.., Nutrizio, M.., Jambrak, Anet Režek., Munekata, P. E.., Lorenzo, J.., Barba, F.., Binello, A.., & Cravotto, G.. (2020). A review of sustainable and intensified techniques for extraction of food and natural products. *Green Chemistry* . http:// doi.org/10.1039/c9gc03878g
11. Cockburn, I., 2004. The changing structure of the pharmaceutical industry.. *Health affairs*, 23 1, pp. 10-22 . **https://doi.org/10.1377/HLTHAFF.23.1.10**.
12. Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M., 2014. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. *Nature Reviews Drug Discovery*, 13, pp. 419-431. https://doi.org/10.1038/nrd4309.
13. Day, D., 2000. Leadership development:: A review in context. *Leadership Quarterly*, 11, pp. 581-613. https://doi.org/10.1016/S1048-9843(00)00061-8.

14. DeMets, D.., & Califf, R.. (2011). A historical perspective on clinical trials innovation and leadership: where have the academics gone?. *JAMA* , 305 7 , 713-4 . http://doi.org/10.1001/jama.2011.175
15. Egeraat, C., & Barry, F., 2009. The Irish pharmaceutical industry over the boom period and beyond. *Irish Geography*, 42, pp. 23-44. https://doi.org/10.1080/00750770902815604.
16. Han, H. (2021). Consumer behavior and environmental sustainability in tourism and hospitality: a review of theories, concepts, and latest research. *Journal of Sustainable Tourism, 29*, 1021 - 1042.
17. Hayler, J.., Leahy, David K.., & Simmons, E.. (2018). A Pharmaceutical Industry Perspective on Sustainable Metal Catalysis. *Organometallics* . http://doi.org/10.1021/ACS.ORGANOMET.8B00566
18. Hayler, J.D., Leahy, D.K. and Simmons, E.M. (2018). A Pharmaceutical Industry Perspective on Sustainable Metal Catalysis. *Organometallics*, 38(1), pp.36–46. doi:https://doi.org/10.1021/acs.organomet.8b00566.
19. Jones, S.M., Smith, A.C., Leach, N., Henrys, P., Atkinson, P.M. and Harrison, P.A. (2023). Pathways to achieving nature-positive and carbon–neutral land use and food systems in Wales. *Regional Environmental Change*, 23(1). doi: https://doi.org/10.1007/s10113-023-02041-2.
20. Kearns, C.., Glantz, S.., & Schmidt, L.. (2015). Sugar Industry Influence on the Scientific Agenda of the National Institute of Dental Research's 1971 National Caries Program: A Historical Analysis of Internal Documents. *PLoS Medicine* , 12 . http://doi.org/10.1371/journal.pmed.1001798
21. Khan, A., & Adnan, N., 2014. Impact of Leadership Styles on Organizational Performance. International Journal of Management Sciences, 2, pp. 501-515.
22. Konduri, N., Rauscher, M., Wang, S., & Malpica-Llanos, T., 2017. Individual capacity-building approaches in a global pharmaceutical systems strengthening program: a selected review. *Journal of Pharmaceutical Policy and Practice*, 10. https://doi.org/10.1186/s40545-017-0104-z.
23. Li, H., Sajjad, N., Wang, Q., Ali, A., Khaqan, Z., & Amina, S., 2019. Influence of Transformational Leadership on Employees' Innovative Work Behavior in Sustainable Organizations: Test of Mediation and Moderation Processes. *Sustainability*. https://doi.org/10.3390/SU11061594.
24. Lofgren, H., 2009. Medicines policy and drug company investments: the Irish experience. *Australian Health Review*, 33, pp. 295-298 . https://doi.org/10.1071/AH090295.
25. Lombardo, F.., Desai, P.., Arimoto, R.., Desino, K.., Fischer, H.., Keefer, Christopher E.., Petersson, Carl., Winiwarter, S.., & Broccatelli, F.. (2017). In Silico Absorption, Distribution, Metabolism, Excretion, and Pharmacokinetics (ADME-PK): Utility and Best Practices. An Industry Perspective from the International Consortium for Innovation through Quality in Pharmaceutical Development.. *Journal of medicinal chemistry* , 60 22 , 9097-9113 . http://doi.org/10.1021/acs.jmedchem.7b00487
26. Marques, C., Moniz, S., & Sousa, J., 2019. Challenges in Decision-Making Modelling for New Product Development in the Pharmaceutical Industry. *Computer Aided Chemical Engineering*. https://doi.org/10.1016/B978-0-12-818634-3.50236-8.

27. McDonald, S. and Oates, C.J. (2006). Sustainability: Consumer Perceptions and Marketing Strategies. *Business Strategy and the Environment*, 15(3), pp.157–170. doi:https://doi.org/10.1002/bse.524.
28. Mo, S., & Shi, J., 2017. Linking Ethical Leadership to Employee Burnout, Workplace Deviance and Performance: Testing the Mediating Roles of Trust in Leader and Surface Acting. *Journal of Business Ethics*, 144, pp. 293-303. https://doi.org/10.1007/S10551-015-2821-Z.
29. Mulki, J., Jaramillo, J., & Locander, W., 2009. Critical Role of Leadership on Ethical Climate and Salesperson Behaviors. *Journal of Business Ethics*, 86, pp. 125-141. https://doi.org/10.1007/S10551-008-9839-4.
30. O'Connell, M., Korner, E., Rickles, N., & Sias, J., 2007. Cultural Competence in Health Care and Its Implications for Pharmacy. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, 27. https://doi.org/10.1592/phco.27.7.1062.
31. Priporas, C., & Vangelinos, G., 2008. Crisis management in pharmaceuticals: evidence from Greece. *International Journal of Pharmaceutical and Healthcare Marketing*, 2, pp. 88-102. https://doi.org/10.1108/17506120810887899.
32. Rijal, S.. (2010). Leadership Style And Organizational Culture In Learning Organization: A Comparative Study. , 14 , 17-26 . http:// doi.org/10.19030/IJMIS.V14I5.19
33. Royne, Marla B. et al. "The Public Health Implications of Consumers' Environmental Concern and Their Willingness to Pay for an Eco-Friendly Product." Journal of Consumer Affairs 45 (2011): 329-343.
34. Scherer, Andreas Georg et al. "Introduction to the Special Issue: Globalization as a Challenge for Business Responsibilities." Business Ethics Quarterly 19 (2009): 327 - 347.
35. Sundgren, M., & Styhre, A., 2006. Leadership as De-paradoxification: Leading New Drug Development Work at Three Pharmaceutical Companies. *Leadership*, 2, pp. 31 - 52. https://doi.org/10.1177/1742715006060652.
36. Tansey, P.., Spillane, J.., & Meng, Xianhai. (2014). Linking response strategies adopted by construction firms during the 2007 economic recession to Porter's generic strategies. *Construction Management and Economics* , 32 , 705 - 724 . http://doi.org/10.1080/01446193.2014.933856
37. Vuorenkoski, L., Toiviainen, H., & Hemminki, E., 2008. Decision-making in priority setting for medicines--a review of empirical studies.. *Health policy*, 86 1 , pp. 1-9 . https://doi.org/10.1016/J.HEALTHPOL.2007.09.007.
38. Whelan, B. (2013). A Framework for Sustainable, Competitive Advantage for the Irish Pharmaceutical Industry. [online] repository.wit.ie. Available at: https://repository.wit.ie/2662/.
39. White, K., Habib, R. and Hardisty, D.J. (2019). How to SHIFT Consumer Behaviors to Be More Sustainable: a Literature Review and Guiding Framework. *Journal of Marketing*, 83(3), pp.22–49. doi:https://doi.org/10.1177/0022242919825649. Frank L. Douglas, Frank L. Douglas, V. Narayanan, Lesa Mitchell and R. Litan. "The case for entrepreneurship in R&D in the pharmaceutical industry." *Nature Reviews Drug Discovery*, 9 (2010): 683-689. https://doi.org/10.1038/nrd3230.
40. Wijoyo, H., 2020. Did Servant, Digital and Green Leadership Influence Market Performance? Evidence from Indonesian Pharmaceutical Industry. *Political Economy - Development: Environment eJournal*. https://doi.org/10.31838/SRP.2020.9.95.

41. Yahya, W.K., Musa, N.D. and Hashim, N.H. (2016). Understanding Environmentally Friendly Consumer Behavior. *Regional Conference on Science, Technology and Social Sciences (RCSTSS 2014)*, pp.909–921. doi:https://doi.org/10.1007/978-981-10-1458-1_82.
42. Afsar, B., Cheema, S. and Javed, F., 2018. Activating employee's pro-environmental behaviors: The role of CSR, organizational identification, and environmentally specific servant leadership. *Corporate Social Responsibility and Environmental Management*, *25*(5), pp.904-911.
43. Aus der Beek, T. *et al.* (2016) 'Pharmaceuticals in the environment-Global occurrences and perspectives', *Environmental Toxicology and Chemistry*, 35(4), pp. 823–835. Available at: https://doi.org/10.1002/etc.3339.
44. Baltagi, Badi H. *The Sustainability of Health Care Systems in Europe*. *Contributions to Economic Analysis*, Emerald Publishing Limited, 22 Mar. 2021.
45. Beek, T., Weber, F., Bergmann, A., Hickmann, S., Ebert, I., Hein, A., & Küster, A., 2016. Pharmaceuticals in the environment—Global occurrences and perspectives. *Environmental Toxicology and Chemistry*, 35. https://doi.org/10.1002/etc.3339.
46. Berry, M.A. and Rondinelli, D.A. (2000) 'Environmental management in the pharmaceutical industry: integrating corporate responsibility and business strategy', *Environmental Quality Management*, 9(3), pp. 21–35. Available at: https://doi.org/10.1002/1520-6483(200021)9:3%3C21::aid-tqem3%3E3.0.co;2-4.
47. Bond, M.. (2010). **Oxford Handbook of Chinese Psychology**. . http:// **doi.org/10.1093/oxfordhb/9780199541850.001.0001**
48. Booth, B., & Zemmel, R., 2004. Opinion: Prospects for productivity. *Nature Reviews Drug Discovery*, 3, pp. 451-456. https://doi.org/10.1038/nrd1384.
49. Bouchard, Maryse., Kohler, J.., Orbinski, J.., & Howard, A.. (2012). Corruption in the health care sector: A barrier to access of orthopaedic care and medical devices in Uganda. *BMC International Health and Human Rights* , 12 , 5 - 5 . http://doi.org/10.1186/1472-698X-12-5
50. Burton-Jones, Alan., & Spender, J.. (2012). The Oxford Handbook of Human Capital. . http://doi.org/10.1093/oxfordhb/9780199532162.001.0001
51. Ding, B. (2018) 'Pharma Industry 4.0: Literature review and research opportunities in sustainable pharmaceutical supply chains', *Process Safety and Environmental Protection*, 119(1), pp. 115–130. Available at: https://doi.org/10.1016/j.psep.2018.06.031.
52. Evans, L.S. *et al.* (2015) 'Understanding leadership in the environmental sciences', *Ecology and Society*, 20(1). Available at: https://doi.org/10.5751/es-07268-200150.
53. Foels, R., Driskell, J., Mullen, B., & Salas, E., 2000. The Effects of Democratic Leadership on Group Member Satisfaction. *Small Group Research*, 31, pp. 676 - 701. https://doi.org/10.1177/104649640003100603.
54. Godman, Brian B et al. "Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?" Expert Review of Clinical Pharmacology 8 (2015): 77 - 94.
55. Green, K.W. *et al.* (2012) 'Green supply chain management practices: impact on performance', *Supply Chain Management: An International Journal*, 17(3), pp. 290–305. Available at: https://doi.org/10.1108/13598541211227126.

56. Grossoehme, D., 2014. Overview of Qualitative Research. *Journal of Health Care Chaplaincy*, 20, pp. 109 - 122. https://doi.org/10.1080/08854726.2014.925660.
57. Hannon, Enda, et al. “The State and Industrial Policy in Ireland: A Case Study of the Irish Pharmaceutical Sector.” *The International Journal of Human Resource Management*, vol. 22, no. 18, Nov. 2011, pp. 3692–3710, https://doi.org/10.1080/09585192.2011.622918.
58. HERNANDO, M. *et al.* (2006) ‘Environmental risk assessment of pharmaceutical residues in wastewater effluents, surface waters and sediments’, *Talanta*, 69(2), pp. 334–342. Available at: https://doi.org/10.1016/j.talanta.2005.09.037.
59. Hogg, M., 2001. A Social Identity Theory of Leadership. *Personality and Social Psychology Review*, 5, pp. 184 - 200. https://doi.org/10.1207/S15327957PSPR0503_1.
60. https://www.semanticscholar.org/paper/3bd7a92abfc475c4c2c4c9fa9944c425c06003a5
61. Jia, J., Liu, H., Chin, T. and Hu, D., 2018. The continuous mediating effects of GHRM on employees’ green passion via transformational leadership and green creativity. *Sustainability*, *10*(9), p.3237.
62. Jung, D. (Don), Wu, A. and Chow, C.W. (2008) ‘Towards understanding the direct and indirect effects of CEOs’ transformational leadership on firm innovation’, *The Leadership Quarterly*, 19(5), pp. 582–594. Available at: https://doi.org/10.1016/j.leaqua.2008.07.007.
63. Kang, Jiyun., Liu, Chuanlan., & Kim, Sang-Hoon. (2013). Environmentally sustainable textile and apparel consumption: the role of consumer knowledge, perceived consumer effectiveness and perceived personal relevance. *International Journal of Consumer Studies* , 37 , 442-452 . http://doi.org/10.1111/IJCS.12013
64. Katsikeas, C., Leonidou, C., & Zeriti, A., 2016. Eco-friendly product development strategy: antecedents, outcomes, and contingent effects. *Journal of the Academy of Marketing Science*, 44, pp. 660-684. https://doi.org/10.1007/S11747-015-0470-5.
65. Kiger, M., & Varpio, L., 2020. Thematic analysis of qualitative data: AMEE Guide No. 131. *Medical Teacher*, 42, pp. 846 - 854. https://doi.org/10.1080/0142159X.2020.1755030.
66. Kola, I. and Landis, J. (2004) ‘Can the pharmaceutical industry reduce attrition rates?’, *Nature Reviews Drug Discovery*, 3(8), pp. 711–716. Available at: https://doi.org/10.1038/nrd1470.
67. Kumar, A. *et al.* (2018) ‘When risks need attention: adoption of green supply chain initiatives in the pharmaceutical industry’, *International Journal of Production Research*, 57(11), pp. 3554–3576. Available at: https://doi.org/10.1080/00207543.2018.1543969.
68. Kümmerer, K., 2009. The presence of pharmaceuticals in the environment due to human use--present knowledge and future challenges.. *Journal of environmental management*, 90 8, pp. 2354-66 . https://doi.org/10.1016/j.jenvman.2009.01.023. Pharmaceuticals in the environment can cause effects on wildlife, and proper risk assessment and management strategies are crucial for preventing environmental contamination.

69. Li, J., 2023. Research on the Development Trend and Prospect of the Pharmaceutical Industry under the Impact of COVID-19. *Highlights in Business, Economics and Management*. https://doi.org/10.54097/hbem.v15i.9228https://doi.org/10.54097/hbem.v15i.9228.
70. Liao, Z. and Zhang, M., 2020. The influence of responsible leadership on environmental innovation and environmental performance: The moderating role of managerial discretion. *Corporate Social Responsibility and Environmental Management*, *27*(5), pp.2016-2027.
71. McDermott, O., Antony, J., Sony, M. and Daly, S. (2021). Barriers and Enablers for Continuous Improvement Methodologies within the Irish Pharmaceutical Industry. *Processes*, 10(1), p.73. doi:https://doi.org/10.3390/pr10010073.
72. Megheirkouni, M., & Mejheirkouni, A., 2020. Leadership development trends and challenges in the twenty-first century: rethinking the priorities. *Journal of Management Development*, 39, pp. 97-124. https://doi.org/10.1108/jmd-04-2019-0114
73. Milanesi, M., Runfola, A. and Guercini, S. (2020) 'Pharmaceutical industry riding the wave of sustainability: Review and opportunities for future research', *Journal of Cleaner Production*, 261, p. 121204. Available at: https://doi.org/10.1016/j.jclepro.2020.121204.
74. Min, M., Desmoulins-Lebeault, F., & Esposito, M., 2017. Should pharmaceutical companies engage in corporate social responsibility. *Journal of Management Development*, 36, pp. 58-70. https://doi.org/10.1108/JMD-09-2014-0103.
75. NGUYEN, H.M., MAI, L.T. and HUYNH, T.L. (2019) 'The Role of Transformational Leadership toward Work Performance through Intrinsic Motivation: A Study in the Pharmaceutical Field in Vietnam', *The Journal of Asian Finance, Economics and Business*, 6(4), pp. 201–212. Available at: https://doi.org/10.13106/jafeb.2019.vol6.no4.201.
76. Nguyen, Ha., Mai, Lam., & Huynh, T.. (2019). The Role of Transformational Leadership toward Work Performance through Intrinsic Motivation: A Study in the Pharmaceutical Field in Vietnam. *The Journal of Asian Finance, Economics and Business* . http://doi.org/10.13106/jafeb.2019.vol6.no4.201
77. O'Mahony, J.., & Coughlan, D.. (2015). The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland's Health System?. *PharmacoEconomics* , 34 , 5-11 . http://doi.org/10.1007/s40273-015-0336-1
78. Paul, S., Mytelka, D., Dunwiddie, C., Persinger, C., Munos, B., Lindborg, S., & Schacht, A., 2010. How to improve R&D productivity: the pharmaceutical industry's grand challenge. *Nature Reviews Drug Discovery*, 9, pp. 203-214. https://doi.org/10.1038/nrd3078.
79. Portugal, E., & Yukl, G. (1994). Perspectives on environmental leadership. *Leadership Quarterly*, 5, 271-276. https://doi.org/10.1016/1048-9843(94)90017-5.
80. Savela, T., 2017. The advantages and disadvantages of quantitative methods in schoolscape research. *Linguistics and Education*, 44, pp. 31-44. https://doi.org/10.1016/J.LINGED.2017.09.004.
81. Sonneveld, P. *et al.* (2013) 'Review of health-related quality of life data in multiple myeloma patients treated with novel agents', *Leukemia*, 27(10), pp. 1959–1969. Available at: https://doi.org/10.1038/leu.2013.185.

82. Spinello, R.A. (1992) ‘Ethics, pricing and the pharmaceutical industry’, *Journal of Business Ethics*, 11(8), pp. 617–626. Available at: https://doi.org/10.1007/bf00872273.
83. Tuan, L.T. (2019) ‘Effects of environmentally-specific servant leadership on green performance via green climate and green crafting’, *Asia Pacific Journal of Management* [Preprint]. Available at: https://doi.org/10.1007/s10490-019-09687-9.
84. Wibeck, V., Dahlgren, M., & Öberg, G., 2007. Learning in focus groups. *Qualitative Research*, 7, pp. 249 - 267. https://doi.org/10.1177/1468794107076023.
85. Wilkinson, J.L. *et al.* (2022) ‘Pharmaceutical pollution of the world’s rivers’, *Proceedings of the National Academy of Sciences*, 119(8). Available at: https://doi.org/10.1073/pnas.2113947119.